

J
103
H7
1966/67
D7
A1
Index

HOUSE OF COMMONS

Special Committee on Drug Costs and Prices
1st Session, 27th Parliament, 1966

INDEX

Compiled by Reference Branch, Library of Parliament

	Page
<i>ABUSES IN THE ADVERTISING OF PRESCRIPTION DRUGS</i>	
Brief, Wilson, Laurence, Member firm Consulting Biologists, Montreal	578-583
<i>ACADEMIC AND INDUSTRIAL CONTRIBUTIONS TO DRUG RESEARCH</i>	
Chain, E.B.	1379-80,1385,2689
<i>ACHROMYCIN</i>	
Discovery, price history	621,627-628
Statistics, comparative	2412-15
<i>ADVERSE DRUG REACTION PROGRAM</i>	
<i>See</i> Food and Drug Directorate, National Health and Welfare Department	
<i>ADVERTISING</i>	
Amount, reduction	2326,2356
Brochure	248-250,400-1,2374
Canada, manufacturers own code	1225,1234
Canada-United Kingdom, comparison	1234
Canada-United States, comparison	547-551,1234
Committee recommendation	2635
Competition	557,566
Contra-indications drug use	496-504,553
Direct mail	357-359,379,398-400, 405,406,417,554-564, 614,651-653,954,955- 957,1200,1379,2385

	Page
ADVERTISING (Cont'd)	
Exhibits, meetings	417
Expense	
Direct mail	357-359, 559-562, 762
Doctor, average amount per	558
Periodicals	555, 580, 1176-77, 1200-1
Prescription dollar breakdown	559-567
Food and Drug Act, regulations, approval	19, 20, 1154, 2249-51
Gimmicks	
Cost	254, 553, 556
Use	227-235, 254-255, 398-399, 409, 563, 565, 569, 1201, 1259-60, 1807
Impact	2379-80, 2476-92
Industry limitation	2230, 2343
Pharmaceutical Manufacturers Association, member companies	95, 226-228, 260, 334, 335
Physicians	
Impact	2313-14, 2348-49
Recommendations	1268-69
Prescription drugs, abuses, problems, recommendations	578-583, 2634-35
Professional journals	401, 402, 416, 548, 555, 614, 653, 1135, 2379, 2381
Restrictions	1230, 1249
Sales dollar, percentage	2326
Scientific manuals, production	256
Special promotions - doctors' golf games, others	554
Types, percentage rating physician's choice	241
United States, Federal Trade Commission regulations	19
<i>See also</i>	
Marketing	

	Page
ALBERTA GOVERNMENT	
Alberta Pharmaceutical Association	
Act, an Act to amend	2298-99,2302,2591-95
Brief	2416-2595
Frawley, J.J., letter	2707-08
Patent and Trademark Institute of Canada, comments	2568-78
Pharmaceutical Manufacturers Association of Canada, statement, comments	2555-67,2689-92
Statements, corrections	2295-97,2302-11
Summary	2543-44
Prescriptions, average price	2299
Special drug programs	2295-96
ALBERTA, PROVINCE	
Drug prices (table)	2579-90
Generic name substitution Brand name products	112-113
AMERICAN COLLEGE OF APOTHECARIES	
Canadian statistics comparison favourable United States	89
AMERICAN HOME PRODUCTS CORPORATION	
Holding company for	
Ayerst, McKenna and Harrison	841,853
Ayerst (U.S.)	843
Ives-Cameron	844
Whitehall	844
Wyeth	841
Other companies	843
AMERICAN MEDICAL ASSOCIATION	
<i>New Drugs</i> with Canadian supplement	421
ANTIBIOTICS	
Cyanamid, brief history development	625-630
Imports Italy, Poland	2234,2239-40
Products, list	593
Research	2357-58,2361

	Page
ANTI-DUMPING DUTY	
<i>See</i>	
Customs Tariff	
Dumping duty	
ARFONAD	
Limited use	750
ARTHRITIS	
Research	849,925
(L') ASSOCIATION DES FABRICANTS DU QUÉBEC DE PRODUITS PHARMACEUTIQUES	
Business per year	458,525
Endorsed most basic ideas Canadian drug manufacturers	457
Members	543
ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY	
Patent law	106
ASSOCIATION OF CANADIAN DRUG MANUFACTURERS	
Brief	523-536
Patents	1440-47
Sales Tax	2089-99
Business per year	458,525,2607
Code of Ethics	469,1373
Dan, L.L., Chairman, statement	1373-77
Financial statements members	461,1373-74
Government standards, members compliance	484
Marketing expenses	2619
Membership	533,1374,2607
Pharmaceutical Manufacturers Association of Canada not similar	492,525
Requirements	458,472
Research	1374,1428-29
Sales tax	2405-6

	Page
ATTORNEY GENERAL'S DEPARTMENT OF ONTARIO	
Book identifying drugs	409
AUREOMYCIN	
History, development	595,596,621,625-630, 661
AYERST LABORATORIES	
Exports from Canada	222,837,872
Research, Company, affiliates, Canada	96,202,832,833,844,863, 871-876
Veterinary research, apportionment cost	854
AYERST, McKENNA & HARRISON LIMITED	
American Home Products	
Holding company	841,853
Sale to	853
Brief	870-883
Costs, dollar breakdown	833,838-841,866-868
Manufacturing, Medical Department	880-881
Marketing products	877-879
Plants foreign countries	862
Premarin	201-202,836-38,860-61, 872,1284-85,1329
Quality control	879
Research	830-837,844-845,860- 861,871-876,2185
Expense	830,833
<i>See also</i>	
Ayerst Laboratories	
Ayerst - United States	
AYERST - UNITED STATES	
Ayerst - Canada, connection	843-844,862
BACKGROUND	
Drug industry, article Maclean's January, 1966, Dreskin	2233-38

	Page
BARLOWE-COTÉ LABORATORY	
Legal proceedings against	478,719,720
BASS, S.S., PROPRIETOR, LONDON DRUGS, LTD.	
Brief	1315-24
Pharmaceutical Association of the Province of British Columbia, letter re mis- leading statements	2407-10
BAUER, R.A.	
<i>Ironic Contrast: US and USSR Drug Industries</i> , with Field, M.G.	510-522
BEAUCHEMIN, GUY, EXECUTIVE SECRETARY, PHARMACEUTICAL MANUFACTURERS ASSOCIATION OF CANADA	
Pricing methods, manufacturer, retail	129-130
BELL-CRAIG PHARMACEUTICALS	
Business sold	768,1435
Chlorpromazine	2019
Patent case	762-774,783-787,2196
<i>See also</i>	
L.D. Craig Limited	
BENADRYL	
Parke, Davis & Company, Ltd.	1027,1037-38,1059
BENSON, HON. E.J., MINISTER OF NATIONAL REVENUE	
Customs, treatment	27-31
Sales Tax	32-34
BLAKELY, W.J.	
Appointed Committee accountant	6-7,2604
Letters to Committee re P.M.A.C. brief; Sales Tax	574-577
<i>Profits of Drug Manufacturing Firms in Canada</i>	2610,2664-73

BOYD COMMITTEE

See

Special Committee appointed by
Minister of National Health and
Welfare to Study Existing Legis-
lation on Investigational Drugs,
April 15, 1966 (Dr. Eldon M.
Boyd, Chairman)

BRAND DRUGS

Are Brand Names for Drugs a Menace?

Wright, Dr. G.F.

1123-26

"Comparative Survey of Quality of
Brand Name and Generic Drugs,
Domestic and Imported, 1965"

2029-55, 2100, 2102

Definition

2048-51

Empire Laboratories, comments

1073-77, 1082-83, 1086,
1095-96

Marketing

12, 16, 17, 112, 321

Physicians prescribing

67, 112, 113, 321-324,

421, 716-717, 1106,

1161-63, 2311-12, 2622

Prices

Difference, non-brand quality

722, 723, 1083, 2100,
2102, 2621-62

Disparity Generic

392

Effect

2621-22

Laws effect

2537-40

Quality, no guarantee

113

Safety, high prices

2327

Therapeutic integrity, assurance

959

BRIANT, DR. PETER C., VICE DEAN, SCHOOL
OF COMMERCE, MCGILL UNIVERSITY

Canada-U.K. pharmaceutical price
comparison

131-134, 141-143, 170-186

Canada-U.S. pharmaceutical price,
comparison

186

Pharmaceuticals, import

177-179

Pricing methods, manufacturer, retail

128-129

	Page
BRISTOL LABORATORIES	
New laboratory	96
BRITISH PHARMACOPOEIA OF DRUGS	
Recognized compendium	16,407
BUTAZOLIDIN	
Statistics, comparative	2412-15
CANADA	
Living standard too high, questioned	1154-55
CANADA ASSISTANCE PLAN	
Assistance cost of drugs	390-391
CANADA PENSION PLAN	
Prescription dollar, influence on	89
CANADIAN ASSOCIATION OF DEANS OF PHARMACY	
Statement	2697-99
<i>See also</i>	
University Faculties of Pharmacy	
CANADIAN CONFERENCE OF PHARMACEUTICAL FACULTIES	
Statement	2697-99
<i>See also</i>	
University Faculties of Pharmacy	
CANADIAN CYSTIC FIBROSIS FOUNDATION	
Brief	1676-91
Disease, nature	1661,1667-68,1674, 1678-80
Drugs	
Income Tax exemption	1663
Program, cost	1662,1665-67,1670- 71,1681-89
Provincial assistance	1662-63,1668-69,1673, 1686-89
Sales Tax, removal	1662-63

	Page
CANADIAN CYSTIC FIBROSIS FOUNDATION (Cont'd)	
History, budget	1661,1677-78,1690-91
Objectives	1665,1678
CANADIAN DRUG FORMULARY	
Costs, lowering	2219
Desirable	2314
Food and Drug Directorate, suggestion	2163
<i>See also</i>	
National Drug Formulary	
CANADIAN DRUG INSTITUTE	
Establishment proposed	541
CANADIAN DRUG MANUFACTURERS	
<i>See</i>	
Association of Canadian Drug Manufacturers	
CANADIAN DRUG PATENTS	
Wright, G.F., Ph.D.	1448-51
CANADIAN FACTS COMPANY LIMITED	
Canadian physician attitudes study, medical mail advertising, pharmaceutical literature, conducted for PMAC	676
CANADIAN FOUNDATION FOR THE ADVANCEMENT OF THERAPEUTICS	
Purpose	235-236,298
CANADIAN GOVERNMENT SPECIFICATION BOARD	
Companies deemed to conform with 74-GP-1	2013
Drug workers, health tests	1502-3,1507-8
Quality control	67,322,1160
Standard for Manufacture, Control and Distribution of Drugs (74-GP-1)	1498-1500,1502,1505-6, 1508,1513-14,1536-46, 1550-55,2012-14

	Page
CANADIAN MEDICAL ASSOCIATION	
Brief	410-422
Recommendations, summary	379-380,422
Code of Ethics	381-383
CANADIAN PHARMACEUTICAL ASSOCIATION, INC.	
Annual Survey of Retail Pharmacy, 24th	1949-80
Brief and statement	50,53-69
Brief, supplementary, and statement	1887-93,1931-80
British Columbia Welfare Department survey	1893-95,1904-5,1937
Committee recommendation meeting with provincial associations, Faculties of Pharmacy, Provincial governments	2635
<i>Compendium of Pharmaceuticals and Specialties</i>	68,407-408,438,1891, 1897-98,1934,1947-48 1891,1940-41,1944-46
"Counting and pouring"	1485
Disciplinary committee	50,54
Identity	1888,1935
Manpower and utilization study	1914,2631
Membership	1895,1933
Patents	115,326,434
Pharmacare	54-55
Presentations, previous	1892-93,1941-43
Recommendations	56
Retail Pharmacy Operations, annual surveys	434-435
Term of Reference of Committee, not in agreement	
CANADIAN SOCIETY OF HOSPITAL PHARMACISTS	
Brief	1490-94
Drug Information Service, recommended	68
Membership	1455,1478-79
Objects, aim	1490-91

	Page
CANADIAN WHOLESALE DRUG ASSOCIATION	
Brief	1604-32
Business, estimate	1573
Discounts	1601,1619-23
Distribution, warehousing statistics	1577
Member companies ownership, control, Canadian	1597
Membership, fees	1573,1606-9,1617-19, 1630-32
Mutual, non-mutual companies	1598
Objectives	1609
Operating Survey 1965	1609,1633-46
Projects	1609-10
Sales tax, elimination	1586,1599-1601,1628- 30
Service Survey	1647-58
"Wholesaler Policy"	1607,1610
CANCER	
Research	859
CATHOLIC WOMEN'S LEAGUE OF CANADA	
Resolution, realistic, Committee report to House of Commons	551
CHAIN, E.B.	
<i>Academic and Industrial Contributions to Drug Research</i>	1379-80,1385,2689
CHAPMAN, DR. R.A., DIRECTOR-GENERAL, FOOD AND DRUG DIRECTORATE, NATIONAL HEALTH AND WELFARE DEPARTMENT	
Food and Drug Act, requirements Statement	13 1991-2000

	Page
CHARLES E. FROSST & COMPANY	
Brief and statement	973-975,1013-21
Employment, wages	1016
Exports	984-988,1000-1,1740-41
Finances, dollar breakdown	1020-21
History	999,1015-16
Marketing	1018-19
Manufacture foreign countries	991,994-995
Merck & Co., Inc., purchase by	21-22,470,974,996,1001-7,1015
Products	1016
Products, sale export markets, letter	1740-41
Quality control	1017-18
Research	974-976,996-999,1003,1015,1017
Sales, prescription, non-prescription drugs, Canada	988-989
CHEMICAL INSTITUTE OF CANADA	
Medical Chemistry Group, letter, memorandum	1127-29
CHEMICALS	
Raw	
Foreign, greatest quantity	493,2241-42
Import	2243
Mark-up	181
Restrictive Trade Practices increases cost	12,493
CHEMISTRY	
Pharmacology, difference	727
CHEMISTS	
See	
Pharmacy Practice	

	Page
CHLORAMPHENICOL Parke, Davis & Company, Ltd.	2216
CHLORDIAZEPOXIDE Roche, Canada	760,799-801,1821,2385
CHLOROMYCETIN (CHLORAMPHENICOL) Import Parke, Davis & Company, Ltd. Statistics, comparative	1512,1528 496,661,1028-31,1037, 1040-42,1048,1059 2412-15
CHLORPROMAZINE Bell-Craig Pharmaceuticals Essendale Mental Hospital Micro Chemicals Limited Prices Smith, Kline & French drug, comments	2019 2005-6,2023-24 1763-64,1788-91,1797, 1815,1829 1763-64,1790 1203,1255
CIBA <i>Clinical Symposium</i>	1218
CLINAZINE <i>See</i> Trifluoperazine	
CLINICAL RESEARCH <i>See</i> Research. Clinical	
CLINICAL SYMPOSIUM Ciba	1218
COLONIAL AGENCIES LIMITED Business	2026

	Page
COMBINES INVESTIGATION ACT	
Advertising	481-482
Director of Investigational Research, report 1961, prescription drugs	17
Infringement, if Associations combine to reduce drug costs	435
Pharmaceutical industry requested prepare brief possible law changes, uniformity packaging, distribution	267
Prices, effect on	256-257, 266-267
COMMISSIONER OF PATENTS	
Compulsory licences	1424-25, 2174-75, 2196
Consultation	1409
Duties	1421-22, 2169, 2196
Food and Drug Directorate, relations	2174-75, 2199, 2248-49
Royalties, setting	2196
<i>See also</i>	
Patent Act	
Patents	
"COMPARATIVE SURVEY OF QUALITY OF BRAND NAME AND GENERIC DRUGS, DOMESTIC AND IMPORTED, 1965"	
Discussion	2029-55
Tables	2100, 2102
COMPENDIUM OF PHARMACEUTICALS AND SPECIALTIES	
Reference Text, Canadian Pharmaceutical Association, Inc.	68, 407-408, 438, 1891, 1897-98, 1934, 1947-48
COMPULSORY LICENCE	
<i>See</i>	
Licences, compulsory	

	Page
CONNAUGHT MEDICAL LABORATORIES	
Research, royalties	202,395,1398-99,2166, 2185
CONSUMERS' ASSOCIATION OF CANADA	
Aim	1152
Brief and statements	1133-39,1169,1171-91
Brief, Pharmaceutical Manufacturers Association of Canada statement on	2694-96
"CONVICTIONS REGISTERED AGAINST DRUG MANUFACTURERS 1963 to 1966"	
Discussion	2073-74
Table	2101,2106
COPIER	
Defined	596-600,648,1416-17
Hoffmann-LaRoche Limited, comments	778,2198
Licences, granting	726,762-780
Marketing, costs	717,765,1010-11,1105, 2398-99
Minor changes possibly dangerous	2171-74
Necessary	1721,1745
Prices, copying system	659-600,662
Racketeer	719,725-726,854,1417
Research	2399
CORTISONE	
Price decrease	2203
COST	
General factors influencing	12
<i>COST OF PHARMACEUTICALS AND MEDICINES IN CANADA 1961-1965</i>	
Research and Statistics Directorate, National Health and Welfare Department	2257-82

	Page
<i>COST OF PRESCRIBING</i>	
<i>See</i>	
United Kingdom, Ministry of Health	
<i>COUNTERFEITING</i>	
Branded products	959-960, 966-967, 1125
<i>CROWN CORPORATION</i>	
<i>See</i>	
Generic Drugs	
<i>CUSTOMS ACT</i>	
Committee recommendations	2616, 2618
<i>CUSTOMS TARIFF</i>	
Alberta Government, recommendations	2307-8, 2341, 2345, 2529-34
British preferential tariff	39
Classification	29-31
"Class or kind", valuation practices	31, 40, 1138, 1148-49, 1187-88, 2308, 2400, 2530-32
Committee recommendations	2618
Computation	31
Dumping duty	
Amount	40
Brand name houses over-protected anti-dumping	1148
Costs, effect	27-28
Defined	41-42
Exemptions	29
Pharmaceutical preparations	29, 30, 40, 729, 2308, 2616-17
Value used, selling price country of origin	1031-32

	Page
CUSTOMS TARIFF (Cont'd)	
Duty	
Amount	42
Impact selling price, survey	30
Imported drugs	38-40,729,864
"Kind", definition	39,2391
Preferential	39
Protection partly responsible high prices	30-35,1186,2341,2345
Royal Commission on Health Services recommendation	27
Valuation	28-29,31,39-40,1138-41
CYANAMID OF CANADA LIMITED	
Brief	593-636
"Lederle" trade name pharmaceuticals	593-595
Letter, definition investments	1738-39
<i>The \$100 million Drug Theft</i>	634-636
Operations	
Agricultural field	645-647
Company	593-600,615-616,623, 637,639,644-647,663, 672,674,679,694,1738-39
Pharmaceutical sales dollar breakdown	600
Purchases from parent Company	637-639
Restrictive Trade Practices Commission Report, recommendation patents, memo- randum	631-633
CYSTIC FIBROSIS	
See	
Canadian Cystic Fibrosis Foundation	
DAILY, ROBERT F., VICE-PRESIDENT, GENERAL MANAGER, SMITH, KLINE & FRENCH	
Statement	889-893

	Page
DAILY, ROBERT F., VICE-PRESIDENT, GENERAL MANAGER, SMITH, KLINE & FRENCH INTER-AMERICAN CORPORATION Research of Company	202-203
DAN, LESLIE, CHAIRMAN, CANADIAN DRUG MANUFACTURERS Prices lowering, proposals Statement	479-482 457-461
DARRACH, DR. MARVIN, HEAD DEPT. BIOCHEMISTRY, FACULTY OF MEDICINE, UNIVERSITY OF BRITISH COLUMBIA "Medical Research and The Drug Industry", letter, statement	887
DAVIDSON, ALAN S., M.D., TORONTO Brief and statement Protection of House of Commons requested	1195-97,1230-73 1195-96
DECADRON Statistics, comparative	2412-15
DECLOMYCIN Discovery, price history	621,628-630
DEFENCE PRODUCTION DEPARTMENT Drugs Purchases Specific purchases Standards Testing	1497,1501,1514-18, 1520-21,1544 1501-2,1550-55 2012-13 1508-9,1515,1519,2020-21
DELMAR CHEMICALS LTD. Business sold Patent case	770 770-780,796-797

	Page
DENHOLM, D.A., PRESIDENT, CANADIAN PHARMACEUTICAL ASSOCIATION Statement	1887-93
DERMATOLOGY <i>Literature of Dermatology</i> , Lederle booklet	651-652
DETAIL MAN <i>See</i> Medical Service Representative	
DIAZEPAM Hoffman-LaRoche Limited	762-779
DICHTER, DR. ERNEST Institute for Motivational Research, study marketing	1258,1266
DISEASES New, drug therapy effect	1228-30,2349-52,2707-8
DISPENSING FEE <i>See</i> Prescription Drugs, Professional fee	
DISTRIBUTION Cyanamid of Canada, Ltd.	603-604
DOCTORS <i>See</i> Physicians	
DOCTOR'S CHOICE: THE PHYSICIAN AND HIS SOURCES OF INFORMATION ABOUT DRUGS Bauer, R.A., Wortzel, L.H., article	2285,2382

	Page
DOMINION BUREAU OF STATISTICS	
Prescription drug index	1433-34
Sales pharmaceuticals, amount	33
DRUG COSTS AND PRICES, SPECIAL COMMITTEE	
Agenda and Procedure Subcommittee	
Appointment	5
Reports	
First	6-7
Second	1069
Third	1931,1935
Blakely, W.J., chartered accountant, appointment	6-7,2604
Corrections, Proceedings No. 26	Issue 32, p. iii
Davidson, Alan S., M.D., House of Commons protection requested	1193,1195-96
Hilliard, Dr. Irwin, per diem allowance <i>In camera</i> sittings	2179,2202 2681-85
Laidlaw, A.M., Legal Counsel, appointment	6-7,2604
Living, travelling expenses, J.K. Lawton, Dr. I.M. Hilliard	1931,1936
Pharmaceutical Manufacturers Association of Canada, second hearing, request	2286,2293-94
Quorum reduced	151
Sales tax removal interim report, recommend- ing, moved, not acted on	448-449,1160
Terms of Reference	5,2603-4
Thurwell, Lt. Col., appearance	1535
Witnesses, freedom from arrest and mole- station	1195-96,1306
<i>See also</i>	
Reports to the House	
DRUG FORMULARY	
Creation	1135
DRUG INDUSTRY	
<i>See</i>	
Pharmaceutical industry	

	Page
DRUG INFORMATION SERVICE	
Coordinated system desirable, committee formed	105,259,305,326
DRUG INSTITUTE FOR CANADA	
Committee comments	2648
Establishment	
Empire Laboratories	1073,1081-82,1097,1103, 1106-7,1114-1120,1403, 2647
Food and Drug Directorate	2097
Wright, Dr. G.F.	2097
DRUG MANUFACTURER	
"Convictions Registered Against Drug Manufacturers 1963 to 1966"	2073-74,2101,2106
<i>See also</i>	
Generic Manufacturer	
Pharmaceutical industry	
DRUG NOTIFICATION PROGRAM	
<i>See</i>	
Food and Drug Directorate, National Health and Welfare Department	
"DRUG RECALLS INVOLVING FOOD AND DRUG DIRECTORATE JUNE 1965 TO JANUARY 1967"	
Discussion	2061-69
Table	2105
DRUG RESEARCH INSTITUTE	
Establishment, suggested	2094-96
DRUG THERAPIES	
Government assistance increased	
chronic illness	422
Physicians require more cost information	327
DRUG TRADE	
<i>See</i>	
Pharmaceutical industry	

	Page
DRUGS	
Appearance similar	1745
Brand name vs. Generic	1285,1299,1306,1320, 2100,2102,2409-10
Bulk	
Canadian manufacture	2241-42
Control, stricter	2112,2242-43
Purity	2241,2248
Clinical trials	1460,1537-38,2170
Committee comments	2647
"Comparative Survey of Quality of Brand Name and Generic Drugs, Domestic and Imported, 1965"	2100,2102
Discussion	2029-55
Costs, high, questioned	1910-11
Crown Assets Disposal Corporation, resale	1510,1525,1534-35
Dated, control	73
Demerit system	1542-43
Diseases, new, cause	1228-30,2349-52,2707-8
Disintegration, dissolution tests	2078,2701,2703
Disposal, unwanted	1534-36
Distributing, servicing, capital required, increase	2152-53
Domestic vs. imported	2100,2102
"Drug Recalls Involving Food and Drug Directorate June 1965 to January 1967"	2101,2105
Discussion	2061-69
"Drugs Analysed for Department of Veterans Affairs"	2100-1,2103-4
Discussion	2055-61
Ethical, definition	27
Expenditures	2277-82
Expiry date	2008-9,2068-69
Government, Federal	
People serviced	1525
Purchases	2616
"Qualified" list	1896-97
Government Provincial, purchases	2616

	Page
DRUGS (Cont'd)	
Hospitals	1461-66,1470-71,1475-77, 1547,2615-16
Expenditures	2277-82
Outpatients	1478-80,1493-94
Testing	1469-70,1474
Iatrogenic diseases	2350
Identification mark finished product, lot number	150
Imported	150,1532-33,1541-45, 2031-32,2052,2056,2100, 2102,2108,2113,2183, 2198,2208,2226
Investigational	1458,1460-61,1463,2109
Pre-clinical submissions, guide for completing	20
Italy, imports	395,454-55,1759-60, 2234,2239-40
Monopoly, competition, ethical market	2287
National stockpile	1525-26
New	
Control, (Chart)	72,73,312,356A
Cost	11,95,1381
Definition	16,149,724,1261,1724, 1771,1995-96,2139-46, 2158,2176-77,2612
Extension, protection period 5 to 10 years, benefits	719,724,1038-39
Hospitals	1464
Marketing barriers	2310
Regulations	11,14,15,149,477-478, 902-905,2159
Nomenclature	2609-10
Patent restrictions, price competition ethical market	2287
Patented	
Costs, prices excessive	1821-23,2183
Prices level	2185

	Page
DRUGS (Cont'd)	
Placebo	1745
Plants inspection	1504-5,1538-39,1542
Foreign countries	1538-47
Predosage form	1476,1483
Prepackage form	1476
Prices	
Alberta Government, recommendations	2355-56,2368-71
Alberta, Province (table)	2579-90
Comparison London, Paris, Berne, Rome, Bonn, Boston, Chicago, Los Angeles, Canada	2412-15,2292-93,2674- 78,2613
Control, competition	2186-88,2227,2231-32, 2310-11,2644-45
Patented, unpatented, behaviour	2187-95
Voluntary restraint program	2647
Quality control	2626-27
Raw	
Analysis certificate	1529
Cost	459
Import	12,181,1087,1530-31
Research	1531
Reactions	2109,2350-52
Recall	2062-69,2071-72,2078, 2101,2105,2109
Safety	501,2335-36,2626-27
Special	
Limited use	750-751,854,1052,2359- 61
Rare illnesses, conditions, free, factory cost	301-302,2626
Standards, other countries, comparison	1532
Synthetic	2171
Testing	
Disintegration	2057
Every batch	2159
Finished, complex	2171

DRUGS (Cont'd)

Withdrawal by companies 571,640-43,2109

See also

Brand Drugs

Emergency Drugs

Generic Drugs

Individual companies

Individual drugs

Pharmaceuticals

Prescription Drugs

"DRUGS ANALYSED FOR DEPARTMENT OF
VETERANS AFFAIRS"

Discussion 2055-61

Table 2100-1,2103-4

DRUGS, DOCTORS AND DISEASE?

Inglis, Brian 458

DUMPING DUTY

See

Customs Tariff.

Dumping duty

DUN & BRADSTREET OF CANADA, LIMITED

Key Business Ratios in Canada 695-703

DYAZIDE

Drug, Smith, Kline & French 950

ECONOMIC COUNCIL OF CANADA

Patents and trademarks survey 2687

THE ECONOMICS OF THE INTERNATIONAL PATENT
SYSTEM

Pemrose, E.T., Mrs. 1348,1353-54

	Page
EDUCATION	
Cyanamid (Lederle), assistance	608-610
Postgraduate, aid	1197-99
<i>See also</i>	
Ontario College of Pharmacy	
Pharmacy Practice	
ELI LILLY & CO.	
Identacode	409
ELLIOTT-MARION CO. LTD.	
Market Swedish product	1414
Patent case	768-780, 799-801
ELLIS, I.C., PHARMACIST, NATIONAL HEALTH AND WELFARE DEPARTMENT	
Statement	1500-1
EMERGENCY DRUGS	
Small quantity, seldom used, made available	12,603-604
EMPIRE LABORATORIES, LTD.	
Advertising, warnings, side effects omitted	497-499, 1040
Brief	1123-26
Chemicals imported	1087
Compulsory licence case	775-780
Drug institute, suggestion	1114-22
Letter to Chairman of Committee	1305, 1327-28
"Look alike" tablets	467
Marketing	1095, 1098, 1105
Prices	1075-77, 1094, 1098-1103
Products manufacturing	1074-75, 1090-92
Quality control	1077
Research	468, 1073, 1078, 1090, 1097
Wright, G.F., President	
Letter	1327-28
Statement	1072-73

	Page
EMPLOYMENT	
Ayerst, McKenna & Harrison, Ltd.	839
Cyanamid of Canada Ltd.	602
Pharmaceutical industry	
Professional, M.D., Ph.D.	209,213,274,288
Total	99,274-275,288,2183-84, 2261-62
ENOVID	
Statistics, comparative	2412-15
EQUANIL	
Statistics, comparative	2412-15
ERSKINE, D.M., DIRECTOR, GENERAL PURCHASING BRANCH, DEFENSE PRODUCTION DEPARTMENT	
Statement	1497-98
EUROPE	
Drug control, some observations	2108-13
Drugs imported	
Bulk, examination	2241
Dosage form	2243
EUROPEAN COMMON MARKET	
Pharmaceutical industry	2110-11
EUROPEAN PHARMACOPOEIA	
Preparation	2111
EXCISE TAX ACT	
Pharmaceuticals	
Definition	32
Exemptions	33
Licensing	32
Under Act, list	32,34

	Page
EXPORTS	
Charles E. Frosst & Company	984-988,1000-1,1007-8
Cyanamid of Canada	593
Parke, Davis & Company, Ltd.	1034-37,1051
Pharmaceutical drugs, preparations, finished ethical	276-277,729,1405
Smith, Kline & French	915-916,944
FAIR TRADE PRACTICES COMMISSION	
Patents, abolition	667
FALSPEN	
Drug, Charles E. Frosst & Company	984-985,992-993,1000
FEE-FOR-SERVICE	
<i>See</i>	
Prescription Drugs. Professional fee	
FIELD, M.G.	
<i>Ironic Contrast: US and USSR Drug Industries with Bauer, R.A.</i>	510-522
FLUOROURACIL	
Limited use	750
FOOD AND DRUG ACT	
Advertising, labelling, printed information	20,303,1179-1180,1992
Consumer, safeguard	10-11,1991
Enforcement, staff	20
Purpose, provisions	1991,2001
Quality control	11-15,1206-8,1992
Regulations	
Cost, influence	14-15,1991-92
Manufacturer, costly	11,13-15,303,855-856
New drug	2255-56
Requirements, outline	13,14
Review	15

FOOD AND DRUG DIRECTORATE, NATIONAL
HEALTH AND WELFARE DEPARTMENT

Adverse Drug Reaction Program	2627
Advertising, approval, regulations	19,20,1154,2249-51
Alberta Government recommendations	2309-10
Beer, Quebec city, contamination	2064-65
Brand, Generic name drugs difference insignificant	2003-4,2028-29,2032-51, 2101-2
Budget, staff forecast 1964-1975	2246-47
Bureau of Scientific Advisory Services	1993
Commissioner of Patents, relations	2174-75,2199,2248-49
Committee recommendations	2612,2615,2627,2646
"Comparative Survey of Quality of Brand Name and Generic Drugs, Domestic and Imported 1965" Discussion	2100,2102 2029-55
Control stronger	1206,1307,1532-33,1541
"Convictions Registered Against Drug Manufacturers 1963 to 1966"	2073-74,2101,2106
Directions for use adequate	1995
Drug Institute for Canada	2097
"Drug Notification" by manufacturer	1994,2000-1,2061,2072, 2080,2083,2085,2176, 2234,2627
"Drug Recalls Involving Food and Drug Directorate June 1965 to January 1967" Discussion	2101,2105 2061-69
Drug Research Institute, suggested	2094-96
"Drugs Analysed for Department of Veterans Affairs" Discussion	2100,2101,2103-4 2055-61
Drugs, new, definition, regulations	1995-97,2061,2253-54, 2646
Drugs, old	2612
Reactions	2255-56
Reclassification new, authority	2108-13,2234-38
Europe, researchers studies	

	Page
FOOD AND DRUG DIRECTORATE, NATIONAL	
HEALTH AND WELFARE DEPARTMENT (Cont'd)	
"Examination of Trifluoperazine Tablets Marketed in Canada"	2114-35
Exports, information	2067
Facilities expanded	2612
Functions	2611-12
Government Health Agency or Independent Non-Profit Organization, suggested	2094-97
Greenberg, Dr. Louis, inspections	2234-38
Human testing, manufacturer, doctors writ- ten permission	211,1460
Imports	
Brand, Generic drugs, quality	2039-41,2102,2206,2209
Control improvement	2199
Jurisdiction	2245
Information bulletin	2615,2646
Inspection	1896,2014-21,2061,2079- 80,2251,2336-37,2339
Biologics	2020-21
Frequency	484,487,1432,1470,1528
Imported	1149,1528-29,1994-95, 2015-22,2066-68,2245
Impossible all drugs	1992,2028
New	597,601,926,1771-72
Quality, no guarantee	113,323,421,601,1431- 32
Results unavailable public	1160,1171-72
"Instances of a Significant Hazard to Health Involving Pharmaceutical Products 1959-1966"	2074-83,2101,2107
Investigation, evaluation, clinical trial	1460-61
Italy, investigation, source Generic drugs coming into Canada, report	395,454-455
Manufacturer	
Marketing first time	1996
Registration, notification by	323,1994,2000-2

	Page
FOOD AND DRUG DIRECTORATE, NATIONAL HEALTH AND WELFARE DEPARTMENT (Cont'd)	
"The National Health Fund"	2094-96
Operation, expansion	1992-93
Patent Office, cooperation	1771
Penalties	2074,2079
Personnel, strengthened, understaffed, underpaid	1206-7,1214-15,1432, 2047,2059-60,2064, 2166-67,2246-47,2612
Pharmaceutical industry	
Changes, regular notification	149
Cooperation	483-484,487,2058-60, 2066
Pharmaceutical Manufacturers Association of Canada	
Cooperation	2057-58
Statement on testimony	2692-93
Quality guarantee better than patent	1157
Reaction program	208,403
Recalls	2062-69,2071-72,2078, 2101,2105
Registration by manufacturer	323,2001
Regulations	2012-15,2646
Regulatory actions	1993-94
Safety all drugs impossible	1992,2028,2686
Sales Tax	2091-93,2098
<i>Some Observations on Drug Control in Europe</i>	2108-13
Standard for Manufacture, Control and Distribution of Drugs, enforcement	1502-5,1725-26
Standards unacceptable all countries	856
Testing	1173,1503-4,1509-10, 1513,1517-19,1522-24, 1527,1530,1988-2010, 2026-28,2047-53,2082, 2168-70,2252
Clinical	2251-52

	Page
FOOD AND DRUG DIRECTORATE, NATIONAL	
HEALTH AND WELFARE DEPARTMENT (Cont'd)	
Disentegration	2057
Imports, cost	2208
Raw, bulk	2241-43,2252
Trifluoperazine, new drug, letter	2138-39
United States authorities, cooperation	926
United States Food and Drug Administration, cooperation	2062
<i>See also</i>	
National Health and Welfare Department	
FOOD AND DRUGS, HOUSE OF COMMONS SPECIAL COMMITTEE, 1964-1965	
Generic name purchasing	112,322
Recommendations	322,2001
Safety of Drugs, report	18,108,312
FORMULARY SYSTEM	
Explanation	1458-59,1493
Hospital prescriptions	1463,1473
National, provincial basis not feasible	1455,1458,1473
Private pharmacies	1482-83,1933
FRAWLEY, J.J., Q.C., SPECIAL COUNSEL IN OTTAWA, GOVERNMENT OF ALBERTA	
Letter re Alberta Government brief	2707-8
FROSST, CHARLES E. & COMPANY	
<i>See</i>	
Charles E. Frosst & Company	
FROSST, J.E., PRESIDENT, CHARLES E. FROSST & COMPANY	
Statement	973-975
GANNON, MISS MARY, EXECUTIVE SECRETARY, CANADIAN SOCIETY OF HOSPITAL PHARMACISTS	
Statement	1455-56

	Page
GANTRISIN	
Statistics, comparative	2412-15
GEIGY	
Patent case, England	200,319,751,1436
GENERIC DRUGS	
Alberta Bill 107, enabling substitution	322
Background information	531-532
Committee recommendation	2609
"Comparative Survey of Quality of Brand Name and Generic Drugs, Domestic and Imported, 1965"	2029-55,2100,2102
Crown corporation manufacture, marketing	393-395
Definition	530,531,1472-73,2048-51
Equivalency	
Food & Drug Directorate cannot guarantee	1206,2336
Nonexistent	727,1124
Food & Drug Directorate investigation	
Italy, report	395,454-455
Foreign-made equivalents	395,421
Hospitals	1463-66
Marketing	12,16,17,112,321-322
Prescribing by physicians	67,112,113,321-324,472, 474,496,1230
Prescriptions possible less than one third	1898-99
Price difference Brand name	392,472,494-496,1084
Purchasing by price alone	322
Quality	113,323,392,1150-53,2100, 2102,2338,2700-6
Volume market	1899
<i>What is Generic Equivalent?</i>	367-371
<i>See also</i>	
Drugs	
Prescription Drugs	

	Page
GENERIC MANUFACTURER	
Jules R. Gilbert, Ltd.	1696-1737,1743-60
Number	2085
Pharmaceutical industry, place	1403-4
<i>See also</i>	
Copier	
GERMANY	
Patents	1411
GILBERT, J.R., JULES R. GILBERT, LTD.	
Statement	1696-97
Testimony, corrections	2289-91
GLOSSAIRE DES TERMES MEDICO-HOSPITALIERS	
French glossary medical terms, Ayerst, McKenna & Harrison	878
GREEN BOOK	
<i>See</i>	
National Health and Welfare Department	
GREEN SHIELD PRESCRIPTION PLAN	
<i>See</i>	
Prescription Services Inc.	
GREGORY, E.G., PRESIDENT, AYERST, MCKENNA & HARRISON LIMITED	
Laboratory operation	202
Statement	829-832
GRYPHON LABORATORIES LIMITED	
Background	1812
Brief	1810-37
Hoffmann-LaRoche	2149
Personnel	1814
Production	1813-15
Quality control	1816-19
GUIDE FOR COMPLETING PRE CLINICAL SUBMISSIONS ON INVESTIGATIONAL DRUGS	
Distribution Committee	20

GUNTON, RAMSAY, M.D., CHAIRMAN,
COMMITTEE ON PHARMACY, CANADIAN
MEDICAL ASSOCIATION

Association, recommendations, summary 379-380

HALL COMMISSION

See

Royal Commission on Health Services
1961-1963

HAPAMINE

Prices

2411

HENDERSON, G.F., PATENT ADVISOR,
PHARMACEUTICAL MANUFACTURERS
ASSOCIATION OF CANADA

Statement

1381-85

HENRY, D.H.W., DIRECTOR, INVESTIGATION
AND RESEARCH (COMBINES INVESTIGATION
ACT), REGISTRAR GENERAL DEPARTMENT

Statement

2182-2202

HILLIARD COMMITTEE

See

Patent Licensing of Drug Manufacturers,
Special Committee, 1965-1966

HILLIARD, DR. IRWIN, M.D., F.R.C.P. (c),
PHYSICIAN-IN-CHIEF, TORONTO WESTERN
HOSPITAL; HILLIARD COMMITTEE, CHAIRMAN

Answers to questions

2157-77

HINCHLIFFE REPORT

See

United Kingdom, Ministry of Health.
Cost of Prescribing

	Page
HIND, A.R., ASSISTANT DEPUTY MINISTER, CUSTOMS, NATIONAL REVENUE DEPARTMENT Customs Tariff	39-40, 42-43
HOECHST PHARMACEUTICALS OF CANADA LIMITED	
Patent case	786
HOFFMANN-LaRoche LIMITED	
Brief and statement	707-708, 757-825
Business, explanation	728, 733-738, 751-753,
Statement	760-761
Citations for cases	795
Distribution, services, cost	2152-53
Financial statement	789-794, 824-825
History	759, 817-818
Indigent Patient Research	719-720
Letters to Chairman of Committee	1305, 1325-26, 2149-53
Micro Chemicals Limited	774-75, 1797-98
Micro Chemicals Limited, Gryphon Laboratories Limited, Paul Maney Laboratories Canada Limited submission, letter	2149-51
Research, cost	760-762, 819-823, 2153
Sainsbury Committee, discussion	2152
<i>See also</i>	
Roche, Canada	
HOSPITALS	
<i>See</i>	
Individual subjects	
HOWSAM, PETER, VICE-PRESIDENT, GENERAL MANAGER, WARNER-CHILCOTT LABORATORIES	
Marketing expense	139
HUMANE SOCIETY OF ONTARIO	
<i>See</i>	
Ontario Society for the Prevention of Cruelty to Animals	

	Page
HUME, F.R., Q.C., TORONTO Prices, Association uniformity, Combines Investigation Act infringement	257,266
HUNTER, ROBERT, CHARTERED ACCOUNTANT; DIRECTOR, ROCHE-ENGLAND Statement	707-708
ILSEY COMMISSION <i>See</i> Royal Commission on Patents, Copyright and Industrial Designs 1954-1956	
IMMUNO (CANADA) LTD. Business Inspection plant, tender	2025 1504-5,1538
IMPERACIN Imperial Chemical Industries	2194-95
IMPERIAL CHEMICAL INDUSTRIES Imperacin	2194-95
IMPORTS Compulsory licence, granting, effect Government encouragement, result Hoffmann-LaRoche, Ltd. Parke, Davis & Company, Ltd.	1422-24 733 1325-26 1039
<i>IN A FEW HANDS, MONOPOLY POWER IN AMERICA</i> Kefauver, Estes, quotes	1196,1256,1261
INDUSTRY DEPARTMENT Chemical industry special survey Drug, purchases Food and Drug Directorate inspection potential drug sources <i>See also</i> Inter-Departmental Advisory Board on Pharmaceutical Standards	2687 1730-31 2012

	Page
INCOME TAX ACT	
Tax incentives, research	205
INDIGENT ASSISTANCE	
Necessary	974
INDIGENT PATIENT PROGRAM	
Hoffman-LaRoche, free drugs	719-720
INFORMATION SERVICE	
Canadian Society of Hospital Pharmacists, comments	1455-56
Physicians, availability	149
Products, prices, independent source for doctors, pharmacists	96,1481-82
University of British Columbia study	1474
INGLIS, BRIAN	
<i>Drugs, Doctors and Disease?</i>	458
INNOVATOR	
Defined	596-600,648,1430-31
Major advance only every 10 - 20 years	733-734,1382
Protection	1418-19
Patent long period, lower prices	719
Product from copier, cost	719
INSPECTION	
<i>See</i>	
Food and Drug Directorate, National Health and Welfare Department	
INSPECTORS	
European countries	2110-11,2365

	Page
"INSTANCES OF A SIGNIFICANT HAZARD TO HEALTH INVOLVING PHARMACEUTICAL PRODUCTS 1959-1966"	
Discussion	2074-83
List	2101,2107
INSULIN	
Royalties	202,1398,2166,2202-3
INSURANCE	
Availability wider	96,115,326,2688
Canadian Medical Association, statement	411-412
Committee comments	2646
<i>See also</i>	
Pharmacare Limited	
Prescription Services Inc.	
INTERDEPARTMENTAL ADVISORY BOARD ON STANDARDS FOR PHARMACEUTICAL MANUFACTURERS, DISTRIBUTORS AND AGENTS	
Function, representation	1498-1500,1503,1507, 1545,2012,2016,2020-21 2012
Standards	
INVENTOR	
<i>See</i>	
Innovator	
IRISH SUGAR COMPANY LIMITED	
United Kingdom Patent Act decision	802-808
IRONIC CONTRAST: US AND USSR DRUG INDUSTRIES	
Bauer, R.A., Field, M.G., Harvard Business Review Sept/Oct 1962	395-396,418,455-456, 510-522,623-624
ISONIAZID	
Tuberculosis drug	860

	Page
ITALY	
Generic drugs, investigation source coming into Canada, report	395,454-455
Patents, research	863-864
IVES-CAMERON	
American Home Products, holding company	844
JULES R. GILBERT, LIMITED	
Brand names	1712-13
Brief	1743-60
Business	1727,1744-45
Copier	1698
Drugs	
Quality	1709-10
Raw, source	1705,1714
Wholesale	1705
Food and Drug Directorate, relationship	1700-4
Hoffman-LaRoche, relations	1701-3
Labels	1712
Marketing, bonuses	1699-1700,1706,1708-9, 1733-34
Prices	1706-8,1710
Production	1697
Quality control	1699,1706,1713
Smith, Kline & French of Canada, relations	1746-50,1838-44
Staff	1697-99
Triperazine (Trifluoperazine)	961,1130,1697,1706, 1711-12
KEFAUVER, ESTES	
<i>In a Few Hands; Monopoly Power in America, quotes</i>	1196,1256,1261

KEFAUVER REPORT

See

United States. Senate Committee on
the Judiciary, sub-committee on
Anti-Trust and Monopoly, 1961. Drug
Prices and Patents Bill S-1552.
hearings 1959-60

KEY BUSINESS RATIOS IN CANADA

Dun & Bradstreet of Canada, Ltd. 695-703

LABELLING

Canada 20
Claims, confusion 2003-11
Generic name directly under trade name,
manufacturers name 1135,1163,1222
Prescription drugs
Name indicated 715,892,898,2352-53,
2634
Suggested list, price indicated 2353-54
Prices code by pharmacist 1164-66,1209,2316-17
United States 19

LAIDLAW, A.M.

Appointed Legal Counsel 6-7,2604

LAROSE, ROGER, VICE-PRESIDENT, CIBA
COMPANY LIMITED

Definition, drug manufacturer 207
Pricing methods, manufacturer, retail 128

L. D. CRAIG LIMITED

Bell-Craig Pharmaceuticals Division case 2149

See also

Bell-Craig Pharmaceuticals

	Page
LEDERLE	
Educational assistance	608-610
<i>Literature of Dermatology</i>	651-652
Medical Service Representative	612-614
<i>The \$100 million Drug Theft</i>	634-636
Operations Canada	594-600,622-623
Trade name pharmaceuticals manufactured Cyanamid of Canada Limited	593
LEGISLATION	
Administration, adherence, costly	62-63
Federal, basic	10-12
Prices, effects	2536-42
LIBRIUM	
Hoffman-LaRoche trade name drug, treatment	720,854,1205-6,1435, 1569,1821
Prices	1290-93,1298-1300, 1323,1514,1569-70,1572
Statistics, comparative	2412-15
LICENCES	
Ayerst, McKenna & Harrison, other companies	853,854
Committee recommendations	2637
Compulsory	
Abolition	743-745,891,1030,1047- 1048,1159,1419,1435
Applicant favoured	1421
Application	1424-25,2174-75,2197, 2636
Prosecution time	1425,2175,2337-38,2390
Cases cited	762-780,900-907,1030- 1032,1054,1436
Committee recommendations	2637
Defense of proprietary rights, cost	723
Empire Laboratories, Ltd., comments	1078-1079,1086,1093, 1108-1112
Extension inhibits growth new research- oriented companies	831

	Page
LICENCES (Cont'd)	
Granting, requirements suggested	147-148
Importance	1437, 2521-22
Imports	865, 1148, 1422-24, 1719, 2223, 2353, 2367-69, 2525- 28, 2689-90
Interpretation, assessment, law un- similar England	741-742, 765
Patent Act Section 41(3)	107-111, 248, 250, 312, 317-318, 617-619, 667, 670, 676-678, 684-685, 714, 736, 740-745, 762-780
Price of drugs, influence	764, 2164, 2172, 2690
Problems	902-907, 2172-73, 2176
Relaxation	1412
Research return	2216-17
Royalty	1435, 2183, 2198, 2367-69
Securing, procedure	1079-80
Smith, Kline & French, comments	891, 948
Supreme Court of Canada interpretation	738-745
Ten last fifteen years	2161, 2164
England, reason for granting	751, 2216
Excise Tax Act, persons, firms, licensed under	32
Food and Drug Directorate, involvement	2231
Import drugs	739, 742, 2365-66, 2522-25
Manufacturer	
"Registration" preferred	500
Unnecessary	488
Patent Drugs secondary manufacturer	96, 109-110
Pharmacies, required	62
Voluntary	148-149, 743, 770-771, 1086, 1431-33, 1436, 1719- 20, 2173-74

LITERATURE

See

Medical Press

	Page
<i>LITERATURE OF DERMATOLOGY</i>	
Lederle booklet	651-652
<i>LOFENALAC</i>	
Dietary supplement provided by Province of Alberta	2296-97, 2300
<i>LONDON DRUGS LIMITED</i>	
Brief	1315-24
Business, explanation	1281-82, 1288, 1295-96, 1302
Staff	1288, 1290
<i>LOOK AT CANADIAN PHARMACEUTICAL RESEARCH</i>	
Wright, G.F.	537-542
<i>LUKAS PHARMACEUTICALS</i>	
Government standard not complied with Prices	469-470 466
<i>MacEACHEN, HON. A.J., MINISTER NATIONAL HEALTH AND WELFARE</i>	
Letter to Committee Chairman	2283
Statement	10-13
<i>MacIVER, CALLUM, FIRST VICE-PRESIDENT, CANADIAN CYSTIC FIBROSIS FOUNDATION</i>	
Statement	1661-62
<i>MACLEAN'S</i>	
Background, article January, 1966, drug industry	2233-38
<i>MARKETING</i>	
Association of Canadian Drug Manufac- turers, practices	468-469, 476, 496, 1237- 64, 2619
Bilingualism, English, French	104, 303, 852, 862, 2361, 2493

	Page
MARKETING (Cont'd)	
Charles E. Frosst & Company	976-991,1002-03,1018-21
Code, Pharmaceutical Manufacturers Association of Canada	260,333-340
Committee recommendation	2619,2635
Excesses	1262-64
Expense	
Ayerst, McKenna & Harrison	833-834,839-840
Cyanamid of Canada	611,623,648-654,751
Davidson, A.S., M.D.	1197,1211-13,1254-62
Doctor, per, Canada-U.S.	547,558
Empire Laboratories Ltd.	1083-84
Government additional restriction suggested	554,557
High	2619-21
Pharmaceutical industry, concern	95,104-105,137-139
Research, quality control, comparison	460
Hoffman-LaRoche, Limited	751-753
Income Tax deductible, maximum 15%	547,558,566-567,581,831,881,927,1043-44,1134,1150,1233
Manufacturers sales dollar, percentage	302,926-928
Parke, David & Company, Limited	1043
Pharmaceutical Manufacturers Association of Canada	350,751-753,2618,2620,2679
Prescription dollar, percentage	104,302,416,475
Reduction	623-624
Safety	105
Smith, Kline & French	958-959
United States, Soviet Union, comparison	140
Films, T.V. closed circuit	957
General practices	32,104-105,302-303,1171
Geography, impact	95,104,303,881,2493

	Page
MARKETING (Cont'd)	
Overloading	1262
Pharmaceutical industry practices	1200
Pharmaceutical Manufacturers Association of Canada	350,751-753,2619-20, 2679,2688
Pharmacists, direct selling	104
Samples of products, literature	234,236-239,360-361, 417,549,565,615,755, 878,956-957,1307,1311, 2619
Service necessary	748-749
Soviet Union	240
<i>See also</i>	
Advertising	
Medical Service Representation	
MAY, C.D.	
<i>Selling Drugs by Educating Physicians,</i> <i>article</i>	1200
MEDICAL DIRECTOR	
Role Cyanamid of Canada	610-611
MEDICAL LETTER	
Integrity	2312,2379
Physicians subscribing	2374,2478
Support warranted	1134,2478
MEDICAL POST	
Advertising	
Authority for drug advertising	1233-34,1247
Canadian	1239,1245
Content percentage of periodical	1237-1238
Cost to advertiser	1241
MacLean-Hunter standards	1234
Advisory medical professionals	1236
Aim founding	1236
Brief	1274-77
Circulation	1235
Content	1236-38

	Page
MEDICAL PRESS	
Control, artificial, results	1276-77
Criticism publications	1218-20,1260-61
Newsletter evaluating drugs, suggested	2310
Paramedical publications	1260-61
Role, financing	1272-74
<i>See also</i>	
Individual titles	
 MEDICAL PROFESSION	
Illegally selling pharmaceuticals, Court case, Doctors, Montreal	386
Pharmaceutical industry, aid	
Conventions, meetings	1198,1201
Postgraduate Education	1197-99
Pharmaceutical industry, pharmacies, relationship	380-386,399
<i>See also</i>	
Physicians	
 "MEDICAL RESEARCH AND THE DRUG INDUSTRY"	
Darrach, Dr. Marvin, statement, letter	337
 MEDICAL RESEARCH COUNCIL	
Grants increased	2625
 MEDICAL SERVICE REPRESENTATIVES	
Activities	95,104,137,236-246,258, 338-341,498,563,612- 614,847,893-895,1201, 1587,1592-93,1598,2380 846-847,877-878
Ayerst, McKenna & Harrison	1002-4,1018
Charles E. Frosst & Company	2620
Committee recommendation	344-345,402,650-651,659, 735-736,1002,2373-74,2620
Compensation and cost to Company	335-336,402
Conduct standards	249
Drug withdrawal handled quickly	485,765,851-852,955,1308- 9,2620
Essential	

	Page
MEDICAL SERVICE REPRESENTATIVES (Cont'd)	
Lederle	612-614,659
Medical Doctors	
Opinions	394-395,399-406,416,612, 1199-1201,2300-1,2315, 2383
Research Services Survey, England, attitude	342
Pharmacists attitude to visits	438
Micro Chemicals Limited	1803-7
Qualifications, training	243,337,343,846-847,895- 897,1201,1213-1214,1597-98
Roche, Canada	752
Smith, Kline & French	893-897,928,954-957
<i>See also</i>	
Salesmen	
MEDICINE AND POLITICS	
Powell, Rt. Hon. J., Minister of Health, United Kingdom	2332
MENLEY & JAMES	
Proprietary pharmaceuticals Smith, Kline & French	897,929
MERCK & COMPANY, INC.	
Operation	1006-7
Purchase of Charles E. Frosst & Company	21-22,470,974
MERCK SHARP & DOHME IN CANADA	
Research	997-999,1007
MICRO CHEMICALS LIMITED	
Background	1812
Brief	1810-37
Business volume	1768-69
Chlorpromazine	1763-64,1788-91,1797, 1815
Compulsory licence cases	772-780,936,960-961
Hoffman-LaRoche	774-75,1797-98,2149- 51

	Page
MICRO CHEMICALS LIMITED (Cont'd)	
Manufacturing	1813,1815
Marketing, costs	1767,1769-70,1803-7
Ownership	1780,1810
Research	1778,1785
Rhone Poulenc, price comparison	1798-1800
Smith, Kline & French drug tests	1781-82
Staff	1768,1779-81,1785-86, 1814
Trifluoperazine	1772-77,1815-18
Vademecum, contraindications	1786-87
MINTZ, MORTON	
<i>The Therapeutic Nightmare</i>	134-135,1196
MOBENOL	
Statistics, comparative	2412-15
MODELL, DR. WALTER, DIRECTOR, CLINICAL PHARMACOLOGY AND ASSOCIATE PROFESSOR OF PHARMACOLOGY, CORNELL UNIVERSITY MEDICAL COLLEGE	
Diseases, new, drug therapy effect	2349-50,2707-8
MONASE	
Upjohn Company	1263,1998-99
MOWATT & MOORE	
Smith, Kline & French, voluntary licence agreement	901-907,935-937,961
Trifluoperazine, manufacture	901-906,935-936,961
MUTUAL HOUSES	
See	
Wholesale	
NARCOTIC CONTROL ACT Administration	11

	Page
NATIONAL DEFENCE DEPARTMENT	
Drugs	
Purchases	1510-11,1525-26
Service personnel foreign countries	1527
Testing	1509-10
NATIONAL DRUG AND CHEMICAL COMPANY OF CANADA	
Ownership	1594,1596-97
Policy	77
NATIONAL DRUG FORMULARY	
Committee comments	2645-46
Consumers' Association of Canada	1150,1178
Medical Doctors, comments	406,407
Prescription Drug Benefit Plan, basis	114,325
Royal Commission on Health Services recommendation, not adequate	68,2645
Wilson, Laurence, comments	579
<i>See also</i>	
Canadian Drug Formulary	
NATIONAL HEALTH AND WELFARE DEPARTMENT	
Assistance Committee	18-19
Drugs	
People serviced	1525
Procurement	1500-1,1515,1526
Testing	1509,1537
Green Book, 1960, Data presently Valid	2182-83,2190-94,2203-4, 2225-26,2228,2203,2310, 2461-73,2613
Risk-profit	2327
Role, responsibility	10-12
<i>See also</i>	
Food and Drug Directorate, National Health and Welfare Department	
Research and Statistics Directorate, National Health and Welfare Department	

	Page
"THE NATIONAL HEALTH FUND" Food and Drug Directorate suggestion	2094-96
NATIONAL PENSIONERS AND SENIOR CITIZENS' FEDERATION Resolutions	2181,2283
NATIONAL RESEARCH COUNCIL Financial assistance some research projects 1962	205
Medical Research Division financed to equal National Institute of Health, United States	1221
NATIONAL REVENUE DEPARTMENT Minister's statement, letter re sales tax	33-34,453,507-509
<i>NEW DRUGS</i> Canadian supplement, American Medical Association	421
NORDIC PHARMACOPOEIA Issued recently	2111-12
OCTO-ANALCO LABORATORIES French-Canadian firm	1374
<i>THE \$100 MILLION DRUG THEFT</i> Theft from Lederle Laboratories	634-636
ONTARIO COLLEGE OF PHARMACY Code of Professional Conduct	1487
Schedule retail prices discontinued several years	440-441
ONTARIO PHARMACISTS' ASSOCIATION Letter, supporting submission Canadian Pharmaceutical Association, assistance Committee	1742

	Page
ONTARIO, PROVINCE	
Government specifications met, Generic, Brand name drugs	1206
ONTARIO SOCIETY FOR THE PREVENTION OF CRUELTY TO ANIMALS	
Letter to Chairman of Committee	1305,1329
PMAC	
<i>See</i>	
Pharmaceutical Manufacturers Asso- ciation of Canada	
PARKE, DAVIS & COMPANY, LTD.	
Advertising warnings, side effects	496-497,1040
Brief	1057-68
Brockville, Ontario plant	1037,1039,1045-47,1050, 1058,1068
Canadian Company, Parke, Davis & Company	1027-28
Financial statements	1042-46,1063-68
Fine chemicals	1068
History	1057-58
Packaging	1067
Patent case before Supreme Court of Canada	740
Patents on drugs	1027-29,1061-63
Price information based five products	2411
Research	1058-63
Staff, salaries	1057,1065
PARNATE (PARSTELIN)	
Smith Kline & French	1198,1203,1263-64,1999- 2000
PATENT ACT	
Alberta Government, recommendations	2306-7
Canadian Drug Manufacturers comments, recommendations	530,1374-77,1405-17, 1438-39,1440-49
Committee recommendations	2639-42
Modification	1395,1405,1411-12,1416

	Page
PATENT ACT (Cont'd)	
Patent and Trademark Institute of Canada, comments, recommendations	1336-40,1363-68
Protection innovator	657-658,845,1764-67, 2196
Section 19: Government may use patented invention	
- Public interest, additional protection	318-319,1061-63,2642
Section 41(1): Chemical products and substances intended for food or medicine	
- Abolished	1383-85,2641-42
- Inadequate, revision necessary	1363-70,1396,1397
Section 41(2): Action for infringement	
- Abolition	1366,2641
Section 41(3): No patent to preclude free manufacture or free sale or use of article for human food or medical purpose	
- Base chemical production not encour- aged	268-270,288,916
- Canada law compared other countries	319,863,1338-39,1375-76, 2640
- Changes suggested	1337-38,1342,1351-52, 1366-68,2637-39
- Compulsory licences	1794-95,1829,2638-41
- Court decisions	314,316-317,781-787, 2637
- Decision Mr. Justice Abbott	1764-66,2196,2216
- Importance	1823-26,1830
- Pharmaceutical Manufacturers Asso- ciation of Canada, comments, re- commendations	106-111,311-321,1062, 1064,1381-85,1421
- Prices, lowering	1793,1826-29
- Protection not sufficient	276,1031,1061-63,1383, 1422

	Page
PATENT ACT (Cont'd)	
- Repealed	788,891,917,962,1030, 1337,1384,1393,1397
- Tribunal be created examine question compulsory licence	1384,1391,1421,2639
Section 67(2)(c): Not meeting demand	
- Implementation provide encourage- ment	318,1383,2642
- Licence not be granted drugs, re- commended	743-745
Strengthening law	
Lower prices	724-725,1439
Research development aided	664-666,668,680,845, 863,924,975,1427
Tribunal	1421
PATENT AND TRADEMARK INSTITUTE OF CANADA	
Alberta Government comments on brief	2568-78
Brief and statement	1334,1359-70
History, membership	1338,1359-60
Licensing, suggestions	788
Pharmaceutical Manufacturers Association brief endorsement	1378
PATENT LAW REFORM INQUIRY COMMITTEE 1944, (MR. KENNETH, SIR KENNETH RAYDON, SWAN, CHAIRMAN)	
Patents, United Kingdom	668,677,1366,1384
PATENT LICENSING OF DRUG MANUFACTURERS, SPECIAL COMMITTEE, 1965-1966	
Canadian Pharmaceutical Association, Inc., comments	1623
Commissioner of Patents, cooperation	2160
Compulsory licence	2172-76
Drug costs not studied	2161-62
Food and Drug Directorate, cooperation	2160,2252-53
Implementation	87,235,678,891,960,1038, 2158

	Page
PATENT LICENSING OF DRUG MANUFACTURERS, SPECIAL COMMITTEE, 1965-1966 (Cont'd)	
Imports	1995,2208
Jules R. Gilbert, Ltd. comments	1723-24,1757-59
Licensing, Patent Act, Section 41(3)	18,314,318,618,678, 684,726,743
Loopholes	2158
New drug	
Applications	1223-24,1923
Definition	1771,1995-96,2139-46, 2176-77,2253-56
Pharmaceutical Manufacturers Association of Canada, endorsement, recommendations	109-110,318,2139-42
Purpose	2164
Quality control procedures	2171-72
Recommendations commended, supported by Committee	2612
Report	144-150,247-250,2155
Safeguards	501,2335-36
Steele, H.B., Ph.D., Associate Professor Economics, University of Houston, Texas, representative Alberta Government, comments	2335-39,2386
PATENT OFFICE	
Food and Drug Directorate cooperation	1771
PATENTED DRUGS	
<i>See</i>	
Drugs, patented	
PATENTS	
Abolition	667,724,740-41,1158-59, 1189-90,1344,1357,1361- 62,1404-5,1417-18,1438, 1697,2198,2207-8,2311, 2395,2526-27
Association of the British Pharmaceutical Industry	106,309

	Page
PATENTS (Cont'd)	
Ayerst, McKenna & Harrison Ltd.	830-832, 844, 849
Background	1441, 2635-36
Benefits	1767
Canada, United States, United Kingdom systems	666-668, 671, 676, 1349-1351, 2635-36
<i>Canadian Drug Patents</i> , Wright, Dr. G.F.	1449-51
Canadian residents less than 5%	2197
Charles E. Frosst & Company	1007-9
Committee comments	2648-49
Consumers' Association of Canada	1141, 1156, 1186, 1189-90
Court cases	200, 319, 740, 746, 751, 1364
Exchequer Court	1758, 2649
Supreme Court	1759
Triple damages	1729-30, 1758, 2649
Cyanamid of Canada, Ltd.	616-619, 679
<i>The Economics of the International Patent System</i> , Penrose, Mrs. E.T.	1348, 1353-54
Expiration	2194, 2636
Foreigners	2635
Granting	1422, 1728-29
Industrial development fostered	308-309
Infringement	312, 490, 599, 723, 1033- 34, 1138
International system	1339-40, 1343, 1346, 1348, 1356
Jules R. Gilbert, Ltd.	1697, 1720, 1728-30, 1756- 59
Market control	668
Monopoly	2168, 2196, 2230-31
New plant development	2206
Parke, Davis & Company, Parke, Davis & Company Ltd.	1027, 1029
Pharmaceutical Manufacturers Association of Canada comments, recommendations	307-321, 1378-1385, 2197
Prescription drugs, cost, effect	2161

	Page
PATENTS (Cont'd)	
Product patent	619,657,667-670,1033-34
Protection	
Brand name houses over-protected	1148,2162-63
Cost of drugs	717-719,1156,1186,1407, 1410-11,2186,2198,2223
Foreign owners, allowed large profits	457,460
Imports	2223
Increase suggested	669-670,1406
Level not warranted	203,460,488-489,530, 1395,1438,2324-25
Necessary	66-67,95,102,106-111, 310-311,396,428-429,618- 619,713,830-831,960-962, 1030,1378,1437,1933,2161
Research, promotion, necessity	616-617,668,709-714,830, 837,865,883,916-918,960, 1061,1156,1399-1401,2161
Ten years	719,1728-29
Three years	1895,1913,1933,2217
Three-five years	1418
Purpose, value of system	307-321,679
Quality, no guarantee	1157
Research	
Cost recovery	2216,2223
Inventions, reward	96,110,308,489,668,2161- 62
Research chemists, important information	204-205,296,846
Rights, buying, expiring	490-491
Substance, process	1396,1404,1411,1425-27, 2196
Term basis	2216
United Kingdom system	667-668,676-678,781-784, 937-938,1338,1350-51
United States system	666-668,1343,1347,2206, 2324-25
<i>See also</i>	
Commissioner of Patents	
Unpatentable Information	

	Page
PAUL MANEY LABORATORIES CANADA LIMITED	
Background, ownership	1811-13
Brief	1810-37
Chlorpromazine	1790
Distribution, sales	1814-15
Hoffman-LaRoche Limited, letter	2149-51
Personnel	1814
Prices	1790
Quality control	1816-19, 2049
Trifluoperazine, manufacture	901-907, 915, 936, 960-962, 1130, 1816-20, 1830-35, 2002-5
PENICILLIN	
Ayerst, McKenna Harrison	845, 850-851, 856-858, 873
Development, cost	297, 2165-66, 2202, 2320
Prices	2189-90, 2195
PENROSE, E.T., MRS.	
<i>The Economics of the International Patent System</i> , reference	1348, 1353-54
PENTIDS	
Statistics, comparative	2412-15
PERNAROWSKI, DR. M., ASSOCIATE PROFESSOR, FACULTY OF PHARMACY, UNIVERSITY OF BRITISH COLUMBIA	
Lecture, <i>The Quality of Generic Drugs</i>	2700-6
Paper, phenylbutazone	1520
Testing drugs	1173, 1998, 2008-10, 2169
PERNAROWSKI, DR. M., VICE-PRESIDENT, CONSUMERS ASSOCIATION OF CANADA	
Statement	1133-36
PFIZER, CHAS., CO. INC.	
Patent case, England	746, 751, 809-816
Terramycin, patent expiry	2194-95

	Page
PHARMACARE LIMITED	
Pharmaceutical insurance	78-79, 115, 326, 372-374, 434
PHARMACEUTICAL ADVERTISING CLUB, MONTREAL, TORONTO	
Direct Mail advertising, cost	560
PHARMACEUTICAL ASSOCIATION OF THE PROVINCE OF BRITISH COLUMBIA	
Letter re misleading statements brief S.S. Bass, November 17, 1966	2407-10
PHARMACEUTICAL INDUSTRY	
Active ingredient manufacturing	2448-54
<i>Background</i> , article Maclean's January, 1966, drug industry	2233-38
Basic purpose, nature	109, 596-600
Brand name, use	467
Canadian market, impact	251, 288, 312
Capital invested, rate of return	2402
Collusion nonexistent	2344
Committee recommendations	2647
Committee requested brief possible changes Combines Investigation Act	266-267
Companies	470, 471, 526, 2607
Canadian takeover	725, 1374, 1387, 2261
Large, Trend to	287, 1171
Market percentage	21, 239, 240, 1992, 2002,
Number	2261, 2606-7
	12, 1045, 2261
Ontario, Quebec	
Ownership	459, 462, 479, 525-528,
Canadian	532, 1373
	21, 459, 526, 2607
Foreign	12, 457, 462, 488, 602, 851,
Competition	1050, 1230, 2212-13, 2224, 2327

	Page
PHARMACEUTICAL INDUSTRY (Cont'd)	
Counterfeiting	466-467,900-907
Dosage forms preparation	460,2454-76,2606
Earnings, net	1734-37,2261
Economic structure	99-100,2261-67
Employees	99,274-275,288,2183-84,2261-62
Ethical manufacturer	1251
Exports	2268-71,2608
Food and Drug Act regulations, new drugs	2256
Food and Drug Directorate Corporation	483-484,487,2058-60,2066
Registration, notification	323,1994,2000-2
Foreign control	2607
Generic manufacturer	463,1251
Groups, three distinct	2607-8
Government, relationship	1253-54
Human pharmaceuticals, percentage	2266
Imitation by companies	476-477
Importance	669
Imports	2183,2268-71,2608
Incentives	1427,1429
"Independents"	2607-8
Industry Department, cooperation	485-486
International aspects	671,2153,2184
Law reform, effect existing firms	2541-42
Legislation, history	1253-54
"Look alike" tablets	466-467,900-907
Loss companies as percentages of all companies	2404
Manufacture poor products	1223
Manufacturer, definition	1135
Manufacturing industry, comparison	2265,2401-4
Manufacturing under compulsory licence	1080-1082
Medical profession	
Aid to	1197-1199
Shares in companies	380-381
National economy, contribution	288

PHARMACEUTICAL INDUSTRY (Cont'd)	573
Nationalization	
Packaging prescription size (pre-packaging)	714-715, 898-899, 981, 1211
Prices	
Competition	479-480, 529-530, 713, 974, 1079, 1142-46, 2343-44, 2347-48
Differences between, within, companies	134-136, 464-467, 529, 1094, 1098-1104, 1161, 1162
Discounts	81, 482, 535, 660, 730, 981, 983, 1094, 1108-12, 1160-61, 1174
Brand name Houses to patients	1152
Factors pricing products	536, 660, 780, 781
Fixing	2325-26, 2344
Hospital, retailer	693, 715, 1311, 1458
Hospitals, government organizations lower charge	60, 62, 80, 136, 435-437, 482-483, 976-979, 1174
Lowering	480
Economic situation	
Proposals Canadian Drug Manufacturers	479-482, 486-487, 530
Mark-up	81, 482, 535, 660, 730, 981, 983, 1094, 1108-12, 1160-61, 1174, 2304
Methods setting	1256-57
Subsidiary, parent company charge	728
Voluntary adjustment by industry	327, 379-380, 388-390, 393, 420-421, 2332-33
Production	1406
Encouragement necessary	12, 493, 1406, 2261
Volume	
Profits	261-266, 1136, 2329
Capital invested, return	99-100, 289, 695-703, 732,
Comparison other industries	2610-11, 2664-73
Cyanamid of Canada Ltd.	616, 1738-39

	Page
PHARMACEUTICAL INDUSTRY (Cont'd)	
Empire Laboratories, Ltd.	1092
Excessive	461,2354-55
Fluctuation new discoveries	734,735
Hoffman-LaRoche, Ltd.	733-736
Manufacturers, percentage	534,1738-39
Prescription dollar breakdown	224-226,415
Risks, comparison	2327-29
Proprietary medicines, percentage	2261,2266
Public service products	98,301-302,750-751,854, 1052,2359-61
Purchases goods, services	
Abroad	99,1171
Canada	99,312
Quality, efficacy, safety, responsibility	1902
Regulatory control	2611-12
Reports on effects of drugs	
Attending physicians	208-210
Company physicians employed full time	209
Food and Drug Directorate	209
Resources employed, rate of return	2403
Responsibility	421,1992
Risks	2327-30
Sales	
Dollar breakdown	833,838-841,2305-6
Rate of return	2402
Selling expenses	2267
Statistics	2261-67
Stock market, companies listing	265
Structure, price	2183-86
Taxes	
Income	100
Sales and excise	100
Testing	
Batches drugs	504-505
Human	210-211
Therapeutically active substances made	
in Canada	207-208,2606
Types	2606
Withdrawal drugs	571,640-643

	Page
PHARMACEUTICAL MANUFACTURERS ASSOCIATION OF CANADA	
Alberta Government brief, statement on Annual Statistical Survey	2689-92 347-356,575
Assets, total, member companies	347
Brief	
Abstract	97-116
Alberta Government comments	2555-67
Clarification certain sections	574-575
Complete, except part printed previous proceedings	279-376
Consumers' Association of Canada, comments	1136,1184-1185
Letter to Committee from W.J. Blakely, Chartered Accountant	574-575
Preamble	94-97
Summary	116-124,280,281
Supplementary	2686-96
Canadian physicians attitude study, medical mail advertising, pharmaceutical literature	676
Code of Marketing Practice	259-260,333-340,1378
Consumers' Association of Canada brief, statement on	2694-96
Food and Drug Directorate, statement on testimony	2692-93
Hearing, second, Association request	2286,2293-94
Human pharmaceuticals	
Cost of foods sold	349
Sales member companies	349
Identity	97,328,1420
Investment survey	100,290,1960-64,2329
Letters to Minister of National Health and Welfare re new drug	2139-46
Marketing expenses (1964), 41 member companies	350,751-753,2619-20, 2679

	Page
PHARMACEUTICAL MANUFACTURERS ASSOCIATION	
OF CANADA (Cont'd)	
Membership	
Application form	329-331
Names, number	240,279,375-376,2083-84,2607
Patents, comments, recommendations	307-321,1378-1385
Prescribed drugs, provision Medicare, Welfare programs, governing principles	114,325
Prescription drugs, price history	2147-48
Principles of Ethics	332
Production	1430,2083-84,2607
Recommendations	96,326
Compulsory licensing	111
Research	1430,2148,2624-25
<i>This is Canada's Prescription Drug Industry</i>	622
Voluntary licences	1431-33
PHARMACEUTICALS	
Antibiotics from Italy, Poland	2234,2239-40
Assessment products, standards, procedures	2701-6
Canadian-United States markets, similarities, differences	2424-32
Company standard, importance buying	473
Competition	192,2227
Contraceptive pills, cost	1317-18
Cost, individual, labour hours, Canada-United Kingdom	167
Definition	27
Excise Tax Act	32
Food and Drug Act	27,32
Distribution, manufacturers	101,186,219,293,535
Expiry date	2008-9,2068-69
Exports	194,224,1740-41,2067,2268-71
Food and Drug Act list, tabled	32
Government tender	436,439,1048-49,1084-86
Hospital purchases	1049

	Page
PHARMACEUTICALS (Cont'd)	
Import	1422-23,2268-71
Chemicals, value	287
Control	12
Finished ethical	30,218,219-221,251,274-276
Mark-up	181
Trade-marked	177-179,190
"Instances of a Significant Hazard to Health Involving Pharmaceutical Products 1959-1966"	2074-83,2101,2107
Labour costs, Canada, United Kingdom, selected countries, comparison	167,170-184,292
Market, company holdings	99
Name, Generic placed under Brand, law	473
Preparations, use in	29
Prices	
Brand-Generic, comparison	2383-84
Canada comparison	
Selected countries	100-101,190,291-292,352-353,1167,1182-83
United Kingdom	131-134,141-143,156-167,170-184,640,643
United States	186-187,191,1037,1187
Demand	2332,2397-98
Economic situation, in line with	431,1029,1136
Government policy, effect	1137-1142,1174,1186-91
Government regulations	11
Hospital, retail, difference	64,102,222,435-437
"Like price for like quantity"	1308,1311,1322,2409
Manufacturers level, various factors influencing high cost	462
Manufacturers practices	101
Mark-up	2304
New drugs, initial pricing	620-621
Restrictive, trade practices increase	12
Subsidiary companies	187
Suggested list price	327,982-983,990

	Page
PHARMACEUTICALS (Cont'd)	
Quality control	587-603,1153-54,1933-34,2371,2692-93
Return policy, Smith, Kline & French	952
Sales	
Allocation, wholesale, retail, hospitals	215-216
Cyanamid of Canada, Ltd. dollar break-down	600
Export	214,216
Human, packaged	99,286,348
Lederle, volume	394
Over-the-counter products (OTC)	2691
Retail pharmacies	99,286,474
Total	214,2691-92
Wholesaler, percentage	474
Testing	2701-6
Veterinary	854,855,2061,2266
Welfare outpatient clinics	446-447
<i>See also</i>	
Drugs	
Individual pharmaceuticals	
Prescription Drugs	
PHARMACEUTICALS ASSOCIATIONS	
Role	1293-94,1319,2408
PHARMACEUTICALS CHEMICAL INDUSTRY	
Compulsory licensing, difficulties	268-270
Development not economically feasible	287-88,2197-98
Fine chemical undeveloped	2183
Production in Canada	99,268-270,287
Tariff imports	268-269
PHARMACEUTICALS MANUFACTURERS	
Definitions	207
Importance	1933

	Page
PHARMACIES	
Centres in city, lower prices	2210
Chain, medical building, profit	1928-30,1976
Committee recommendations	2635
Costs, profits, income	1951-75,2231,2276
Discount, cut-rate	75,1135,2311,2316, 2348
Licensing	1920
Mail Order	75-76,2311,2345-47, 2634
Number	62,1925-26,2272-73
Ownership	
Doctor	62,72-77,381-382,428, 1084,1295-96,1320, 1890,1919-20
Pharmacist	1919
Products unrelated, subsidization	57,60,1312,1319,1322, 1932-33,2209-11,2324, 2410,2632
Staffing	1932
Super market	2311,2316
<i>See also</i>	
Pharmacy Practice	
Prescription Drugs	
PHARMACISTS	
<i>See</i>	
Pharmacy Practice	
PHARMACOLOGY	727
Chemistry, difference	
PHARMACY PRACTICE	71-72,1320
Clinic-operated	2609,2635
Committee recommendations	59,443-445
Consumer dollar breakdown	1891,1940-41,1944-46,
"Counting and pouring"	2632-34

	Page
PHARMACY PRACTICE (Cont'd)	
Discipline Associations, power	1302,1319,1321,1925
Earnings	1312,1313,1322,1323
Generic substitution	67,1153,1473
Government beneficiaries, drugs	62
Hospitals	1455,1461-66,1491,1935
Licensing	62
Manpower and utilization study	1888
Number	62,105
Dispensing only	88
Retail	88
Persons using pharmacies, average number	57
Pharmaceutical dollar distribution	1889
Pharmacists per pharmacy	62
Physicians	
Dispensing, owning	62,72-77,381-82,428, 1084,1295-96,1320,1890, 1919
"Kickback"	1304-5,1320,2409
Partnership	77,381,1919,2634
Prescriptions	
Dispensed, average per pharmacist	1290,1312
Statistics	1889
Prices	
Community pharmacy level completely justified	442
Mark-up	1215-16,1284,1290-93, 1299-1300,2633
Variation	1920-21,2633-34
Profits	57,219,534,1889,1895, 1951-53
Public, relationship	1488-89
Responsibilities	715-17,1491-93,1906, 1915-16,1919,1924,1944- 46
Retail	55-56,70-72,1932,2323- 24
Advertising	1485-87
Survey, Canadian Pharmaceutical Asso- ciation, Inc.	1932,1936,1949-80
Role, change	1944-46,2632-34
Salaries	1312-13,1980
Owner pharmacy	1900-1

	Page
PHARMACY PRACTICE (Cont'd)	
Sales	
Gross average per pharmacy	57
Prescription, percentage	2632
Total	57,99
Services	
Complete necessary	69
Public	440,1209-10
Universities degree granting	1888,1935
University requirements	1288-89,1267,1297-98, 1319-20,1476-77,1484- 85,2407-8,2632,2697-99
<i>See also</i>	
Canadian Pharmaceutical Association, Inc.	
Pharmacies	
Prescription Drugs	
PHARMACOPOEIAL STANDARDS	
Limitations of existing	2112-13
PHARMA RESEARCH CANADA LIMITED	
Laboratory, new	96
Research Division European firm	199
PHENYLBUTAZONE	
Paper, Pernarowski, Dr. M.	1520,2043-46
Testing	1519-20,1997-98,2043- 46
PHYSICIANS	
Committee recommendation	2609
Education	2285
Pharmacy	
Dispensing, owning	62,72-77,381-82,428, 1084,1295-96,1320,1890, 1919-20
"Kickback"	1304-5,1320,2409
Role	2614-15
<i>Selling Drugs by Educating Physicians</i>	1200
United States, Hart bill	1890,1919-20,2285
<i>See also</i>	
Medical Profession	

	Page
<i>PILL COUNTING-FACT OR FALLACY?</i> Rotenberg, G.N., B. Sc. Phm.	1944-46
PITMAN-MOORE Dow Chemical Division	920
PREDNISOME Price variance	1161-62, 1175, 2375
PREMARIN Ayerst, McKenna & Harrison drug Statistics, comparative	201-202, 836-838, 860- 861, 872, 1284-85, 1329, 2185 2412-15
PRESCRIPTION DRUG BENEFIT PLAN Royal Commission on Health Services, recommendation	114, 324
PRESCRIPTION DRUGS Canadian manufacture Committee recommendations Cost Dispensing Dollar breakdown Canadian Medical Association, comments Consumer Ingredients Manufacturer Demand, factors influencing Dosage packaging Expenditure per capita Annual Average Forms pre-inscribed Generic name prescribing Generic Terminology possible less than one third	99, 287 2629, 2632-33, 2647 58, 1891-96, 1910, 2495- 2502 413-414 59, 127, 444-445, 1932, 1936 59 128-129, 185-188, 214-223, 285-286, 574 2503-14 898-899, 1289, 1496 56 57, 64 1480 382, 1144-45, 1151, 1179, 1301 1898-99

PRESCRIPTION DRUGS (Cont'd)

Government assistance individuals,
cost relief

388-389

Hospitals

1461-66,1477

Imported

99,287

Industry characteristics

97-98

Legislation, dollar effect

1902,1933

National economy, contribution

98

Number

Capita, pharmacy, year

57

Dispensed per day

1923,1974

Increase, 5-year chart

61

Preparations available

105

Physicians

Pharmacist instructions

715-717,1906,1944-46

Prescribing Generic, Brand name,
freedom

831,882,2327

Prescriptions written not dispensed

2322-23

Prices

Alberta, average

2299

Average

57-58,285,419-20,881,
1907-9,1912,1937,2612-
13

Canada Pension Plan influence

89

Code on label, prescription forms, by
pharmacist

1164-66,1209,2316-17

Comparison, increase, 5-year chart

61,65

Differences, comparison before purchase,
"shopping around"

430,1142-46,1208-9,1342,
2352-53,2631-32

Manufacturer

101,128-131,293-295

Mark-up

83-84,129-130

Retail

60,128-131,140-141,1164-
65,1938-41,2612-13

Suggested list price

2352-54,2628,2646-47

Utilization, comparison

58-61,1910-11

	Page
PRESCRIPTION DRUGS (Cont'd)	
Professional fee	59-60,140-141,379,386-388,389,408,413-414,420,431-434,447-448,1135,1178-79,1480-81,1908-10,1921,1927-28,1980,2647
Cost plus method	982,1135,1167-69,1178-79,1908,1916-18,1925,2211,2299,2547-54,2628,2633
Record-keeping	1923-24
Retail subsidizing hospital, government agencies	60,62,80,85,435-437
Sales amount, relation total sales	1916,1918,1954-55,2274-82,2324
Statistics	1889
Stock in pharmacies	1106
Subsidization other items, sales	57,60,1312,1319,1322,1932-33,2209-11,2324,2410
Substitution pharmacist	716
Supply factors influencing	2434-2503
United States prices higher	1889
Value per year, 1955-64	57-58
<i>See also</i>	
Dominion Bureau of Statistics	
Drugs	
Pharmaceuticals	
PRESCRIPTION SERVICES INC.	
Abuse	1848-50
Brief	1873-84
Cystic fibrosis coverage	1848,1857-58
Drugs	
Dollar amount	1851,1860
Exclusions	1863-65

PRESCRIPTION DRUGS (Cont'd)

Pharmacists	
Fee, membership	1850,1854-56,1865-70, 1876,1879-80
Financial support	78-79,1871
Payments to	1851
Premiums	434,1851,1854,1863-65
Prescriptions	
Benefits	1881-84
Cost, average	1862,1877
Increase	1862-63
Processed	1851
Promotion	1853
Regulations	1850,1857-59,1861,1865, 1879,2646
Subscribers	1851,1853-54,1871-72

PROFESSIONAL FEE

See

Prescription Drugs. Professional fee

PROFESSIONAL INFORMATION LETTER

Food and Drug Directorate, current
information

1135,1150,1178

PROFESSIONAL SERVICE REPRESENTATIVES

See

Medical Service Representatives

PROFITS OF DRUG MANUFACTURING FIRMS
IN CANADA

Blakely, W.J.

2610,2664-73

PROMOTION

See

Advertising
Marketing

	Page
PROPRIETARY ASSOCIATION OF CANADA	
Sales pharmaceuticals, amount	33
PROPRIETARY OR PATENT MEDICINE ACT	
Administration	11
Firms registering products	21
PROVINCIAL PHARMACEUTICAL ASSOCIATIONS	
<i>See</i>	
Canadian Pharmaceutical Association Inc.	
PROVISION, DISTRIBUTION AND COST OF DRUGS IN CANADA, STUDY	
<i>See</i>	
Royal Commission on Health Services	
PSYCHIATRY	
Drugs used	1204-5
PUBLICATIONS	
<i>See</i>	
Medical Press	
PUBLIC EYE	
Television program	2397
QUALITY CONTROL	
Ayerst, McKenna & Harrison	879-881
Canadian Government specifications Board	67,112,1041
Charles E. Frosst & Co.	1017,1018
Copier, compliance law	730-731
Cost	
Canadian Pharmaceutical Manufacturers Association, survey	15,102,295,356,1175
Food and Drug Directorate survey	460
Necessary	94,881
Restrictive Trade Practices Commission report	15
Empire Laboratories, Ltd.	1077
Essential	306,415

	Page
QUALITY CONTROL (Cont'd)	
Food and Drug Act	10-12,67
Food and Drug Directorate, committee check standard	1173
Laws applied more strictly	1221-25
Lederle Laboratories	596-598,601-603
Methods, Canadian drug manufacturers	487
Overplayed to justify high prices	460
Royal Commission on Health Services, recommendation	113
Smith, Kline & French	944-947,959
<i>See also</i>	
Safety	
 QUALITY OF GENERIC DRUGS	
Lecture Pernarowski, M., Ph.D.	2700-6
 QUINIDINE	
Price increase, behaviour, referred Agenda and Procedure Subcommittee	5
 REPORTS TO THE HOUSE	
First	152
Second and Final	2599-2679
Background	2604-5
Committee recommendations	
Adverse Drug Reaction Program, publicity	2627
Canadian Pharmaceutical Association, provincial associations, Faculties of Pharmacy, Provincial governments meet to discuss practice of phar- macy particularly items specified	2635
Customs Act amended drug imports	2618
Customs Act amended dumping duties	2616
Food and Drug Directorate personnel, facilities be expanded	2612
Food and Drug Directorate publish information bulletin	2615,2646

	Page
REPORTS TO THE HOUSE (Cont'd)	
Food and Drug Regulation amended	
"new drug" status	2646
Licensing, compulsory	2637
Marketing, promotional expenses	2619
Medical, pharmacy students instructed	
generic nomenclature	2609
Medical Service Representatives be	
paid by salary not commission	2620
Patent Act	2639-42
Prices differences, comparison before	
purchase	2632
Prices, suggested list, abolished	2647
Professional fee, cost price plus	2633
Research	2625-26
Royalties	2626
Sales Tax, Federal removed prescrip-	
tion drugs	2629
Summary	2651-52
Tariff Board review drug tariff	
structure	2618
Trade Marks Act	2644
Conclusions	2649
Contents	2801-2802
Costs Canadian consumer	2612-14
Costs, prices, factors affecting	2616-45
Drug industry in Canada	2606-12
Other proposals made and considered	2645-49
Physician, hospital, government role	2614-16
Terms of Reference	2603-4
REPRESENTATIVES	
<i>See</i>	
Medical Service Representatives	
RESEARCH	
Ayerst, Research Laboratories	96,202,830,833,844-845, 848,871-876,1802,2207
Basic, applied	197,297,857-860,1379- 82,1434,2318-21,2342-43, 2357-60,2434-45,2622-23

	Page
RESEARCH (Cont'd)	96
Bristol Laboratories	
Canada	
<i>A Look at Canadian Pharmaceutical Research</i> , Wright, Dr. G.F.	537-542, 1127-29
Canadian firms	464, 468, 489, 1414, 2185, 2207, 2321-22, 2622-26, 2687, 2689
Discoveries, insulin, premarin	201-202
Expansion	300, 1430, 2201, 2214-15, 2318
International, benefit, cost	200-201, 264-265, 2687
Limited, reason	550, 605-606, 711, 1175, 1394, 1802, 2162, 2208, 2214, 2357
Necessity	66, 95-96, 102, 414-415, 1388-89, 2199, 2214
Pharmaceutical industry, investment	679-680, 1397-98, 2162, 2222-23, 2687
Purchase	2200-1
Charles E. Frosst & Company	974-976, 996-999, 1003, 1010
Clinical	1434
Costs	690, 1344
Importance	
Pharmaceutical companies cooperation, universities, hospitals, physicians	606-607, 680-682, 751, 855, 1052, 2162
Committee recommendation	2625-26
Connaught Medical Laboratories	202, 395, 1398-99
Costs	1434, 1778-79, 2358-59
Allocation	272-273, 936-937, 1394, 2329-30
Ayerst, McKenna & Harrison, Ltd.	830, 833
Canada	300, 459
Drug cost closely linked	96, 98, 2200
Empire Laboratories Ltd.	1090

	Page
RESEARCH (Cont'd)	
Heavy compared major discoveries	733-738,2200
Hoffman-LaRoche, Ltd.	753
Increasing	98,102-103,107,830
International	95,102,107,199-201, 295,1391-93,2218
Lederle	605
New drug, increase 5 years	299
Pharmaceutical industry	100,103,199-201,289, 529
Pharmaceutical Manufacturers Asso- ciation of Canada	351,1381
Recovery, estimated time	1388,1391,1394
Safety	105
United States	459
Cyanamid of Canada, Ltd.	680,683,686,689-690, 2322
Expenditure	606,680
Policy	605-606,658,683
Empire Laboratories, comments	1073,1090,1091,1097
Employment, member companies, pharmaceuti- cal Manufacturers Association of Canada	351,1361
Exports, increase	1406
Government assistance	
Financial	107,205,310,550,769, 1261
Incentives	669,1221,1343,1389-90, 2200,2331-32,2625,2651
Hoffmann-LaRoche	760-762,2207
Industries, other, comparison	731
Innovator, recovery cost	721-722
International	
Benefits Canadian consumer	200-201,203,710
Cost	95,102,107,199-201
Importance	203,300,1341,2199
Laboratories	96,107,202,830,1405,1434
Lederle	395,604-607,625-630,664- 666,680-682

	Page
RESEARCH (Cont'd)	
<i>Look at Canadian Pharmaceutical Research</i>	537-542
"Medical Research and the Drug Industry"	
Darrach, M.	337
National Research Council financial assistance	205
Natural products main source raw materials	856-857
Over-emphasized	1388
Parke, Davis & Company, Ltd.	1047, 1058-61
Patent protection	106-108, 296, 309-310, 668, 718, 830, 835-836, 846, 1388
Personnel	
Canada	66, 689-690
Number, degrees	103, 301
Pharmaceutical Manufacturers Association of Canada	1430, 2148, 2624-25
Pharma-Research Canada Limited	96, 198-199
Product development	3445-48
Productivity	102-103
Public service products	98, 301, 2359-60
Smith, Kline & French	96, 202-203, 890, 917- 918, 922-925, 947-951
Tax incentives	202-203, 205, 310, 831, 2197
Testing	
Clinical	212, 298, 541
Preclinical	541
Trends	197-199, 204, 296-298, 688, 1261, 1379-81
Universities	1728, 2208, 2225-26, 2342
Veterinary	680
Warner-Lambert	96
Wright, Dr. G.F.	537-542, 1127-29, 1396-97

RESEARCH AND STATISTICS DIRECTORATE,
NATIONAL HEALTH AND WELFARE DEPARTMENT

*Cost of Pharmaceuticals and Medicines in
Canada 1961-1965* 2257-82

See also
National Health and Welfare Department

	Page
RESTRICTIVE TRADE PRACTICES COMMISSION	
Green Book, information prices	437,661,1156
Recommendations, summary	2661-62
Report concerning the manufacture, distribution and sale of drugs, 1963	
Antibiotics prices	27,661-662
Capital investment, rate of return	262,2329
Dumping duty rules	27,2616
Generic prescribing	112,322
Patents	95,106,307,314-15,617,631-633,831,865,1354,2198
Quality control	15
RETAIL	
<i>See</i>	
Pharmacies	
Pharmacy Practice	
Prescription Drugs	
RHONE-POULENC S.A.	
Background	1812
Micro Chemicals Limited, price comparison	1798-1800,1826-28
RIMIFON	
Hoffman-LaRoche, Limited, drug	719-721
ROCHE, CANADA	
History	817-818
Research	709
Subsidiary Hoffman-LaRoche, Limited	707
<i>See also</i>	
Hoffman-LaRoche, Limited	
ROSS, HON. J.D., M.D., MINISTER OF PUBLIC HEALTH, PROVINCE OF ALBERTA	
Statement	2295-97,2334

	Page
ROTENBERG, G.N., C. Sc. Phm. <i>Pill Counting-Fact or Fallacy?</i>	1944-46
ROYAL COMMISSION ON HEALTH SERVICES 1961-1963	
Provision, Distribution and Cost of Drugs in Canada, study	11,21
"Quality of Drugs" section, analysis Pharmaceutical Manufacturers Asso- ciation of Canada	113,323,362-366 2649
Recommendations	
Advertising deductible income tax, maximum 15%	547,558,566,567,581, 881,927,1043-44,1134, 1150,2331
Anti-dumping regulations administration changes	28,2617 112,322
Generic prescribing	739,995-996,2198,
Licences import drugs	2223
National Drug Formulary	68,114,406-407
Patent protection	95,106-107,109,307- 308,310,315,667,1418, 1354,2031,2198
Prescription Drug Benefit Plan	114,324
Tariff review drugs	27
Trade Marks Act amendment	1103-4,1189,1368-69, 2031
Voluntary drug price restraint program	327
Report, extract respecting drugs	2658-60
Research	103,300,461,709
Sales Tax	37,690-692
Trade Marks Act amended permit import drugs	177,180
ROYAL COMMISSION ON PATENTS, COPYRIGHT AND INDUSTRIAL DESIGNS 1954-1956	
Cyanamid of Canada, Ltd., comments	617
Product patents	667
Recommendations	
Canadian Patent Act Section 41(1)	1352,1384,1438,2231,2663
Compulsory licensing	676-678,741,1352,2249
Licences import drugs	739
Royalties	317

	Page
ROYAL INSTITUTE OF PATENTS	
Compulsory licensing outlived usefulness	938
ROYALTIES	
Amount	
Awarded, method	746-748, 1112, 2339-40
Inadequate	738-740, 1030, 1801, 2196, 2397
Changes suggested	1352
Charles E. Frosst & Company	985, 992-994, 999-1001
Commissioner of Patents	
Setting	2196
Statement	316
Committee recommendations	2626
Connaught Medical Laboratories	202, 1398-1399
Cyanamid of Canada, Ltd.	604, 664, 682, 684, 687
Exchequer Court and Supreme Court rulings	316-317
Imports, licensing	2198, 2367-69
Insulin, premarin, large	202
Necessary to industry	109, 289, 315
Parke, Davis & Company, Ltd.	1028
SAFETY	
Costs	
Essential	306, 415
High, unnecessary	457
Increasing	105, 306
Production direct bearing	22, 94, 105, 415
Research, marketing increased	306-307, 650
Government regulations	106, 111, 307
Special Committee on Food and Drugs, 1964	18
<i>See also</i>	
Quality Control	

	Page
SAINSBURY COMMITTEE	
Hoffmann-LaRoche Limited, discussion	2152
United Kingdom, investigate drug costs and prices (not parliamentary)	707-708,763,766-767, 1436,1727-28
SALESMEN	
Empire Laboratories, Ltd.	1085,1098,1105-6
<i>See also</i>	
Medical Service Representatives Wholesale	
SALES PROMOTION	
<i>See</i>	
Advertising	
Marketing	
SALES TAX, FEDERAL	
Benson, Hon. E.J., Minister of National Revenue, statement, letter	33-34,453,507-509 2405-6
Canadian Drug Manufacturers, comments	1890,1892,1907-8,1932
Canadian Pharmaceutical Association, Inc. Committee recommendation	2629
Drug Research Institute funded by tax, suggestion	2629
Exceptions	2627
Excise Tax Act, treatment	32
Food and Drug Directorate, comments, relationship	2091-93,2098,2246-47
Letter to Committee from W.J. Blakely, Chartered Accountant	576-577
Manufacturers price	32-33,36-37,115,127- 131,755
"The National Health Fund"	2094-96
Pharmaceuticals, amount paid	33,37,1908
Prescription drugs	33,35-37,59,83,85,96, 2545-47

	Page
SALES TAX, FEDERAL (Cont'd)	
Price of drugs	
Effect	576,620-622,690-692,756, 835,978,1021,1053,1146- 47,1166-67,1186,2229, 2534-36,2627-29
Saving minute if removed	1284,1317
Pyramiding	36-37,130-131,396-398, 1921,2627
Removal	
Alberta Government	2309,2323
Ayerst, McKenna & Harrison	882
Canadian Medical Association	379,414
Canadian Pharmaceutical Association, Inc.	443-444,1907-8,1911
Canadian Wholesale Drug Association	1586,1599-1601,1628-30
Charles E. Frosst & Company	975
Committee interim report to House recom- mending removal moved, not acted on	448-449,1160
Consumers' Association of Canada	1141-42,1191
Parke, Davis & Company Ltd.	1053,1064
Pharmaceutical Manufacturers Asso- ciation of Canada	115,127,326
Retail price	129-131
United Kingdom, none, purchase tax varies	174
SASKATCHEWAN MEDICAL SERVICES INCORPORATED	
Drug cost plan	79
SEARLE COMPANY	
Sales, taxes, not income	461
SEARLE-PERNAROWSKI PAPER	
University of British Columbia	1469,2010
<i>Selling Drugs by Educating Physicians</i>	
May, C.D., article	1200

	Page
SHOWALTER, DR. H.A., CHIEF, CONSUMER CHEMICALS DIVISION, INDUSTRY DEPARTMENT Statement	1498-1500
SMITH KLINE & FRENCH	
Brief	939-969
Canadian operations	461,907-915,929,934,941- 959
Exports	915-916,944
Financial statistics	942-944
Jules R. Gilbert, Ltd.	1696,1838-44
Manufacturing	944-947,964-965
Marketing	893-900,930-931,951-959
Menley & James Laboratories, proprietary division	897,941-942
Micro Chemicals Limited	1781-82
Mowatt & Moore production licence	901-907
Paul Maney Laboratories Canada Limited	1816-20,1830-35
Product integrity	959-967
Quality control	944-947
Research	96,202-203,890,917-918, 922-925,931-936,947-951
Sales statistics	890,942
Statement, suggestions	890-893
Trifluoperazine, new drug, letters <i>See also</i>	2136-39
Stelazine	
SMITH, KLINE & FRENCH INTER-AMERICAN CORPORATION	
Letter re Jules R. Gilbert	1838-44
Trifluoperazine	1130
SOGENA, INC.	
French-Canadian firm	1374
SOME OBSERVATIONS ON DRUG CONTROL IN EUROPE	
Food and Drug Directorate	2108-13

	Page
SPECIAL COMMITTEE APPOINTED BY MINISTER OF NATIONAL HEALTH AND WELFARE TO STUDY EXISTING LEGISLATION ON INVESTIGATIONAL DRUGS, APRIL 15, 1966	
Recommendations commended, supported, by Committee	2612
STATISTICS	
Up-to-date, more comprehensive, needed	327
STANDARDS	
<i>See</i>	
Canadian Government Specification Board	
Individual subjects	
Inter-Departmental Advisory Board on Pharmaceutical standards	
STEELE, H.B., Ph.D., ASSOCIATE PROFESSOR ECONOMICS, UNIVERSITY OF HOUSTON, TEXAS; REPRESENTING ALBERTA GOVERNMENT	
Articles written re drugs	2297
Statement	2302-11
STELAZINE	
Assay	1519-20
Imported, finished, bulk form	2190-94
New drug status	1989
Price	2190-91
Smith, Kline & French	951,968,1069,1198,1203, 1422,1821-22,1830-44, 2002-5,2010-11,2114-35, 2191
<i>See also</i>	
Trifluoperazine	
STEWART, DR. BRIAN, DIRECTOR, PHARMA-RESEARCH CANADA LIMITED	
Pharmaceutical companies coordination, cooperation	204
Research, statement	198

	Page
STREPTOMYCIN	
Ayerst, McKenna & Harrison	845
STRONG COBB ARNER OF CANADA, LTD.	
Tetracycline	1175
SWAN COMMITTEE	
<i>See</i>	
Patent Law Reform Inquiry Committee	
1944 (Mr. Kenneth, Sir Kenneth	
Raydon, Swan, Chairman)	
SWEDEN	
Fees for registration	2109
SYNTEX LIMITED	
Business	2025
TARIFF	
<i>See</i>	
Customs Tariff	
TARIFF BOARD	
Committee recommendation	2618
Drug tariff, review	27-28, 38
TAX INCENTIVES	
Incomes Tax Act, amendments 1961, 1962	205
Research	202-203, 206
TELEVISION	
<i>Public Eye</i>	2397
TERRAMYCIN	
Antibiotic	661
Pfizer, patent expiry	2194-95

	Page
TETRACYCLINE	
Antibiotic	593-594
Discovery, history, therapeutic superiority	625,627-628,1175
Prices	1175,1256,2383
THALIDOMIDE	
Use	2381-82
<i>THERAPEUTIC NIGHTMARE</i>	
Mintz, Morton	134-135,1196,1265
<i>THIS IS CANADA'S PRESCRIPTION DRUG INDUSTRY</i>	
Pharmaceutical Manufacturers Association of Canada	622
TOLBUTAMIDE	
Comparative study some brands available in Canada	2285,2290
TRADE AND COMMERCE DEPARTMENT	
Industry guidelines	672-674
TRADE MARK	
Explanation	1368
Protection, higher prices	1186,1189,2520
TRADE MARKS ACT	
Alberta Government, recommendations	2306-7,2528-29
Committee recommendations	2644
Consumers' Association of Canada recommendations	1189
Patent and Trademark Institute of Canada, comments, recommendations	1355-56,1368-70,2643
Strengthening assistance research	680
TRANCOPAL	
Winthrop, price	2190-91,2194

	Page
TRIFLUOPERAZINE	
Cost, potency, different manufacturers	901-907, 915, 920-921, 935-937, 960-962, 968- 969, 1069, 1130, 1517- 18, 1697, 1706, 1711, 1770, 1772-77, 1791, 1816- 22, 1829-44, 1988, 2003-7 2114-35
Examination tablets marketed in Canada	2114-35
New drug status	1989, 2136-39
TRIFLURIN	
See	
Trifluoperazine	
TRIPERAZINE	
See	
Trifluoperazine	
TUBERCULIN TABLETS	
Prices	2411
TURNBULL, J.C., EXECUTIVE DIRECTOR, CANADIAN PHARMACEUTICAL ASSOCIATION, INC.	
Cut-rate pharmacies	75
Doctor dispensing drugs	75
Patent legislation	428-429
Pharmaceutical services	69-72
Statement	50
"222"	
Statistics, comparative	2412-15
UNITED KINGDOM	
Antibiotic supplies discontinued from	
Italy, Poland	2234, 2239-40
Comptroller of Patents	1421
Compulsory licences	1435-36
Drug control	2112, 2244
Drug laws changes	2112
Dunlop Committee	2244
Patent Appeal Tribunal	1421
Patents	667-668, 676-678, 781- 784, 937-938, 1350-51 2332
Prices voluntary regulation scheme	2332

	Page
UNITED KINGDOM, MINISTRY OF HEALTH	
<i>Cost of Prescribing</i>	
Final report	798
Patent protection	787
Prescribing freedom	324
Research	199,295-296,721-722,734, 760,769-770,2687
Voluntary Price Regulation Scheme	763,782-785
UNITED STATES	
"Drug Abuse Control Amendments 1965"	
Public Law 89-74, 89th Congress H.R.2	966-967
Internal Revenue Service, authority, level profit	29
Patents	666-668,1343,1347,2206, 2324-25
Pharmaceutical industry	
Advertising ethical drugs	29
Foreign subsidiaries	29
Profits	28-29,35
Pharmacopoeia of Drugs	16,407
Prescription price average higher Canada	1889,1938
Senate Bill S-260, introduced by Mr. Hart, prohibiting sale by licensed practitioners of drugs or devices prescribed by them	1890,1919-20,2285
Senate Committee on the Judiciary, sub- committee on Anti-Trust and Monopoly, 1961. Drug prices and Patents, Bill S-1552, hearings 1959-60	1189,1205,1216,1222,1225, 1254,1262,1337,1859,2225, 2303,2336,2394,2461,2707-8
USSR drug industry, comparison	510-522,2374-75
UNITED STATES, FOOD AND DRUG ADMINISTRATION	
Drugs	
Clinical testing	2171
Older, testing for efficacy	2058
Food and Drug Directorate, cooperation	2062
Generic, Brand name drugs	2048
Therapeutic equivalency, research	2686

	Page
UNIVERSITY OF BRITISH COLUMBIA Information Service, study	1474
UNIVERSITY OF BRITISH COLUMBIA, FACULTY OF PHARMACY Pernarowski, M., Ph. D., Associate Professor, letter, lecture	2699-2706
UNIVERSITY FACULTIES OF PHARMACY Committee recommendations <i>See also</i> Canadian Association of Deans of Pharmacy Canadian Conference of Pharmaceutical Faculties University of British Columbia, Faculty of Pharmacy	2635
UNPATENTABLE INFORMATION Passing to others	849-850
"USAN" Drug names simplification	406
USSR Drug industry comparison US	510-522
VADEMECUM Commercial book of drugs	407,496,500-503,553,559, 568,650,651,927,1040, 1766-67,1897-98
VETERANS AFFAIRS DEPARTMENT Drugs People serviced Purchases Testing	1525 1506-7,1511-12,1515-17, 1525-26 1509-10,1513,1529
VETERINARY PHARMACEUTICALS <i>See</i> Pharmaceuticals. Veterinary	

	Page
VETERINARY RESEARCH	
Ayerst Laboratories	854
VITAMINS	
Analyzed 1965	2100
Regulations, advertising	2073,2075,2079
VOLUNTARY AGENCIES	
Free drugs	390-391
VONTROL	
Smith, Kline & French	950
WAREHOUSING	
Cyanamid of Canada, Ltd.	603-604
WARNER-CHILCOTT	
Retail, hospital prices similar	1311
WARNER-LAMBERT	
Laboratories, new	96,202
WARNOCK HERSEY	
Trifluoperazine test	1782,1844
WESTON, D.R., SECRETARY-MANAGER, CANADIAN WHOLESALE DRUG ASSOCIATION	
Statement	1567-68
WHITEHALL	
American Home Products, holding company	844
WHOLESALE	
Advertising	1584
Charles E. Frosst & Company	979-980
Committee comments	2630-31
Delivery speed	1574,1586
Distribution	
Costs	1586,1591-93,2493-95
Percentage	474,535,895,1045,1577- 80,1583-84,1592

	Page
WHOLESALE (Cont'd)	
Doctors direct	1593
Drugs	
Over-the-counter, percentage	1585-86
Prescription, percentage	1585
Generic Houses	1579
Hoffman-LaRoche policy	1569
Industry in Canada	1611-15
Manufacturer	
Cooperation	1576-77
Direct selling	1574,1577,1579-80
Relationship	216-217,894,1577-78
Mutual Houses, rebate	1568-69,1594
Non-drug merchandise	1588-89
Pharmacists shares	1568
Pre-packaging	1595-96
Prices	
Mark-up	535,1568-73,1575-76
Role	2324
Products carried	1585
Professional pharmacist on staff	1586
Profit, percentage	534,1598-99,1620,2629
Re-packaging	1572,2631
Retail and wholesale companies	1574-75,1601-2
Salesmen	1585,1587,1592,1597
Saskatchewan National Drugs	1594
Service necessary	66,414,1567-68,1605
Smith, Kline & French policy	894,930-931
Tele-tips discount	1572-73,1609
Wholesaler	
Definition	1607
Functions	1615-17
WIGLE, DR. W.W., PRESIDENT, PHARMACEUTICAL MANUFACTURERS ASSOCIATION OF CANADA	
Brief presentation	93-125
Pharmaceutical manufacturer, definition	207
Research, statement	197
Statement	1377-81

	Page
WILKINSON, W.A., PRESIDENT, PRESCRIPTION SERVICES INC. Statement	1847-48
WILSON, LAURENCE, MEMBER FIRM CONSULTING BIOLOGISTS, MONTREAL Brief and statement	547-551, 578-583
WINDSOR PREPAID PRESCRIPTION PLAN Prescription insurance	78-79
WINTHROP Trancopal, price	2190-91, 2194
WRIGHT, DR. G.F., PRESIDENT, EMPIRE LABORATORIES LTD. <i>A Drug Institute for Canada</i> <i>A Look at Canadian Pharmaceutical Research</i> <i>Are Brand Names for Drugs a Menace?</i> Statement	1114-22 537-542, 1127-29 1077, 1086, 1123-26 1072-73
WRIGHT, DR. G.F., RESEARCH CONSULTANT, CANADIAN DRUG MANUFACTURERS Canadian Drug Patents	1396-97, 1449-51
WYETH American Home Products holding company	841
APPENDICES	
Issue 4	
A - Report special ad hoc committee studying matters involving patent licensing of drug manufacturers	144-150
Issue 5	
A - Brief, Pharmaceutical Manufacturers Association of Canada (tables, chart)	279-356
1 - Comparative prices of drugs in Canada and UK	156-165
2 - Comparison of real cost of Canadian and UK drug prices	166
3 - Cost of individual drugs in labour hours	167

APPENDICES (Cont'd)

Issue 6		
A - Brief, Canadian Medical Association	410-422	
Issue 8		
A - Letter from E.J. Benson, Minister of National Revenue, re sales tax	507-509	
B - <i>Ironic Contrast: US and USSR Drug Industries</i> Bauer, R.A., Field, M.G.	510-522	
C - Brief, Canadian Drug Manufacturers	523-536	
D - Brief, Wright, G.F., <i>A Look at Canadian Pharmaceutical Research</i>	537-542	
E - L'Association des Fabricants du Québec de Produits Pharmaceutiques, members	543	
Issue 9		
A - Letter from W.J. Blakely, Chartered Accountant, re brief P.M.A.C.	574-575	
B - Letter from W.J. Blakely, Chartered Accountant, re Sales Taxes	576-577	
C - Brief, Laurence Wilson, Member firm of Consulting Biologists, Montreal	578-583	
Issue 10		
A - Key Business Ratios in Canada, Dun & Bradstreet of Canada, Limited	695-703	
Issue 11		
A - Brief, Hoffmann-LaRoche Limited	757-825	
Issue 12		
A - Brief, Ayerst, McKenna & Harrison Limited	870-883	
Issue 13		
I - Brief, Smith, Kline & French	939-967	
II - Trifluoperazine Tenders, Smith Kline & French Inter-American Corp.	968-969	
Issue 14		
A - Brief, Charles E. Frosst & Company	1013-1021	
Issue 15		
- Brief, Parke, Davis & Company, Ltd.	1057-1068	

	Page
APPENDICES	
Issue 16	
A - A Drug Institute for Canada, Wright, Dr. G.F.	1114-22
B - Are Brand Names for Drugs a Menace? Wright, Dr. G.F.	1123-26
C - Letter from Medicinal Chemistry Group, Chemical Institute of Cana- da	1127-29
D - Trifluoperazine, Smith Kline I.A. Corporation	1130
Issue 17	
I - Brief, Consumers Association of Canada	1171-91
Issue 18	
A - Brief, Davidson, Alan S., M.D., Toronto	1250-73
B - Brief, Medical Post	1274-77
Issue 19	
A - Brief, London Drugs Limited	1315-24
B - Letter from Hoffman-LaRoche Limited	1325-26
C - Letter from Dr. G.F. Wright, Presi- dent, Empire Laboratories Limited	1327-28
D - Letter from Tom I. Hughes, General Manager, Ontario Humane Society	1329
Issue 20	
A - Brief, Patent and Trademark Insti- tute of Canada	1359-70
Issue 21	
A - Brief, Patents, Canadian Drug Manufacturers	1440-47
B - Brief, Canadian Drug Patents, Wright, G.F. Ph.D.	1448-51
Issue 22	
A - Brief, Canadian Society of Hospital Pharmacists	1490-94
1 - Comparative prices of drugs in Canada & U.S.	149
2 - Comparison of retail costs of Canadian and UK drug prices	150
3 - Cost of individual drugs in labour hours	167

APPENDICES (Cont'd)

Issue 23		
A - Defence Production Department specific drug purchases	1550-55	
B - Canadian Government Specifications Board standard for Manufacture, Control and Distribution of Drugs	1556-64	
Issue 24		
A - Brief, Canadian Wholesale Drug Association	1604-32	
B - Canadian Wholesale Drug Association, Operating Survey 1965	1633-46	
C - Canadian Wholesale Drug Association, Service Survey	1647-58	
Issue 25		
A - Brief, Canadian Cystic Fibrosis Foundation	1676-91	
Issue 26		
A - Letter, Cyanamid of Canada Limited, re definition investment	1738-39	
B - Letter, Charles E. Frosst & Company re sale products export markets	1740-41	
C - Letter, Ontario Pharmacists' Asso- ciation	1742	
D - Brief, Jules R. Gilbert, Ltd.	1743-60	
Issue 27		
A - Brief, Micro Chemicals Limited, Gryphon Laboratories Limited, Paul Maney Laboratories Canada Limited	1810-37	
B - Letter, Smith, Kline & French Inter- American Corporation	1838-44	
Issue 28		
A - Brief, Prescription Services Inc.	1873-84	
Issue 29		
A - Brief, supplementary, Canadian Phar- maceutical Association, Inc.	1931-80	

	Page
APPENDICES (Cont'd)	
Issue 30	
A - Brief, Canadian Drug Manufacturers, sales tax	2089-99
B - Food and Drug Directorate, Summary of Data on Drugs	2100-7
C - Food and Drug Directorate, Some Observations on Drug Control in Europe	2108-13
D - Food and Drug Directorate, Examination of Trifluoperazine Tablets Marketed in Canada	2114-35
E - Correspondence Trifluoperazine, "new drug"	2136-46
F - Letter from Pharmaceutical Manufacturers Association of Canada	2147-48
G - Letter from Gowling, MacTavish, Osborne & Henderson re patents	2149-51
H - Letter from Hoffman-LaRoche Limited	2152-53
Issue 32	
A - <i>Cost of Pharmaceuticals and Medicines in Canada 1961-1965</i> , Research and Statistics Directorate, National Health and Welfare Department	2257-82
B - Letter from Hon. A.J. MacEachen, Minister of National Health and Welfare	2283
Issue 33	
A - Pharmaceutical Manufacturing Industry in Canada comparison all Canadian manufacturers	2401-4
B - Sales Tax on Pharmaceuticals, Canadian Drug Manufacturers	2405-6
C - Letter, Pharmaceutical Association of the Province of British Columbia re brief S.S. Bass, November 17, 1966	2407-10

APPENDICES (Cont'd)

D - Letter, Parke, Davis & Company, Ltd. Price information based five products	2411
E - Price comparison certain drug, London, Bonn, Boston, Chicago, Los Angeles, Paris, Canada	2412-15
F - Brief, Government of the Province of Alberta	2416-2595
Issue 34	
A - Supplementary submission Pharmaceutical Manufacturers Association of Canada, February 1967	2686-96
B - Statements, Canadian Conference of Pharmaceutical Faculties; Canadian Association of Deans of Pharmacy	2697-99
C - Letter M. Pernarowski, Ph.D. enclosing copy lecture at University of British Columbia	2699-2706
D - Letter, J.J. Frawley re Alberta Government brief	2707-8
Issue 34 (Second and Final Report)	
A - Witnesses Heard	2654-57
B - Royal Commission on Health Services 1961-1963, extract from report respecting drugs	2658-60
C - Restrictive Trade Practices Commission summary of recommendations	2661-62
D - Royal Commission on Patents, Copyright and Industrial Designs 1954-1956 recommendations S.41 Canadian Patent Act	2663
E - Profits of drug manufacturing firms in Canada	2664-73
F - Table comparative prices to retailer twelve most commonly used drugs different countries	2674-78

	Page
APPENDICES (Cont'd)	
G - Marketing expenses (1964) of 41 companies (members PMAC)	2679
List	2715-17
BRIEFS	
- Canadian Pharmaceutical Association, Inc.	53-69
- Cyanamid of Canada Limited	591-636
- See also Appendices	
BRIEFS, STATEMENTS, CORRESPONDENCE	
Index	2712-13
DOCUMENTS	
- <i>A Comparative Study of Some Brands of Tolbutamide Available in Canada.</i> Canadian Medical Association Journal	2285
- <i>Doctor's Choice: The Physician and His Sources of Information About Drugs, Bauer, R.A., Wortzel, L.H.</i>	2285
- <i>The Fortunes of Economic Reform Legislation: The Case of the Drug Amendments Act of 1962, Steele, Henry</i>	2286
- <i>Monopoly and Competition in the Ethical Drugs Market, Steele, Henry</i>	2287
- <i>Patent Restrictions and Price Competi- tion in the Ethical Drugs Industry, Steele, Henry</i>	2287
- <i>Physicians and Continuing Education - An Educational Trust-How Well Are We Fulfilling It? Williams, D.H. M.D.</i>	2285
- <i>A Study of Canadian Physicians Attitudes to Medical Mail Advertising and Phar- maceutical Literature</i>	588

DOCUMENTS (Cont'd)

- United States Senate Bill S-260
introduced by Mr. Hart, prohibiting
sale by licensed practitioners of
drugs or devices prescribed by them 1890,1919-20,2285
- *See also*
Appendices
- Tabled and not printed 2714

WITNESSES

- Aitken, Donald, M.D., Assistant
Secretary, Canadian Medical Asso-
ciation 383-397
- Allmark, M.G., Assistant Director
General, Drugs, Food and Drug Direc-
torate, National Health and Welfare
Department 1234,1510-48,2030,2046-
47,2239-44
- Bass, S.S., Proprietor, London Drugs
Limited 1281-1314
- Beauchemin, Guy, Executive Secretary,
Pharmaceutical Manufacturers Asso-
ciation of Canada 129-131
- Benson, Hon. E.J., Minister of National
Revenue 27-44
- Bertrand, J.A., Manager, Medical Pro-
ducts Department, Cyanamid of Canada
Limited 639-694
- Bethel, R.F., Technical Manager, Smith,
Kline & French 905-915
- Blanch, J.M., Vice President, Finance,
Charles E. Frosst & Company 975-1003
- Briant, Dr. P.C., Vice Dean, Director,
School of Commerce, McGill University;
Pharmaceutical Manufacturers Asso-
ciation of Canada 128-143,170-277
- Buyske, Dr. D.A., Director of Research,
Ayerst, McKenna & Harrison Limited 848-861

	Page
WITNESSES (Cont'd)	
- Cameron, D.M., Canadian Pharmaceutical Association	1903
- Chapman, Dr. R.A., Director-General, Food and Drug Directorate, National Health and Welfare Department	13-21,1987-2088,2234-56
- Coffin, A.F., Vice President, Sales, Charles E. Frosst & Company	979-1005
- Cook, H.D., President Abbott Laboratories Limited; Pharmaceutical Manufacturers Association of Canada	234
- Cook, J.M., President, Micro Chemicals Limited	1763-1808
- Daily, R.F., Vice-President, General Manager, Smith, Kline & French	889-938
- Daily, R.F., Vice-President, General Manager, Smith Kline & French Inter-American Corporation	202-272
- Dalby, A.J., Director of Marketing, Smith, Kline & French	893-931
- Dan, Leslie, Chairman, Canadian Drug Manufacturers	457-505,1373-1439
- Davidson, Alan S., M.D., Toronto	1195-1232
- Davidson, R.M., Officer in Charge, Merger and Monopoly Section, Register General Department	2205-24,2232
- Denholm, D.A., President, Canadian Pharmaceutical Association	1887-1930
- Ellis, I.C., Pharmacist, National Health and Welfare Department	1500-48
- English, Dr. H.E., Executive Vice President, Consumers Association of Canada	1136-69
- Erskine, D.M., Director, General Purchasing Branch, Defence Production Department	1497-1548
- Fallis, Fred, M.D., Committee on Pharmacy, Canadian Medical Association	381-406
- Fox, Nathan, Council Delegate, Quebec Branch, Canadian Society of Hospital Pharmacists	1458-84

	Page
WITNESSES (Cont'd)	
- Fralich, J.S., President, Hoffman-LaRoche Limited	707-756
- Frawley, J.J., Q.C., Special Counsel in Ottawa, Government of Alberta	2295-98, 2365-77, 2397-99
- Freisen, Major A.R., National Defence Department	1513
- Frosst, J.E., President, Charles E. Frosst & Company	973-1011
- Gannon, Miss Mary, Executive Secretary, Canadian Society of Hospital Pharmacists	1455-78
- Gendron, Dr. Claude, Medical Director, Cyanamid of Canada Limited	641-690
- Gilbert, J.R., Jules R. Gilbert, Ltd.	1696-1737
- Godfrey, J.M., Q.C., Legal Counsel, Parke, Davis & Company, Ltd.	1032-56
- Gregory, E.G., President, Ayerst Laboratories; Pharmaceutical Manufacturers Association	202-275
- Gregory, E.G., President, Ayerst, McKenna & Harrison Limited	829-869
- Gunton, Ramsay, M.D., Chairman, Pharmacy Committee, Canadian Medical Association	379-409
- Hardman, Dr. A.C., Director, Bureau of Scientific Advisory Services, Food and Drug Directorate, National Health and Welfare Department	2011
- Hayhurst, W.L., President, Patent and Trademark Institute of Canada	1333-70
- Henderson, G.F., Q.C., Patent Advisor, Pharmaceutical Manufacturers Association of Canada	191-200, 1381-1437
- Henry, D.H.W., Director, Investigation and Research (Combines Investigation) Registrar General Department	2182-2232

WITNESSES (Cont'd)

- Hilliard, Dr. Irwin, Physician-in-Chief, Toronto Western Hospital 2157-77
- Hind, A.R., Assistant Deputy Minister Customs, National Revenue Department 39-43
- Hollett, A., Director, Bureau of Operations National Health and Welfare Department 2023-27, 2060-70, 2250
- Howsam, Peter, Vice-President, General Manager, Warnar-Chilcott; Pharmaceutical Manufacturers Association of Canada 139, 184-273
- Hume, F.R., Barrister, Pharmaceutical Manufacturers Association of Canada 125-141, 169-267
- Hunter, Robert, Chartered Accountant; Director, Roche-England 707-755
- Larocque, B.J., Pharmacist, Veteran Affairs Department 1513-49
- Larose, Roger, Vice-President, CIBA Company, Limited; Pharmaceutical Manufacturers Association of Canada 128, 204-245
- Lawton, J.K., Canadian Pharmaceutical Association, Inc. 1900-30
- Levi, Dr. L., Chief, Pharmaceutical Chemistry Division, Food and Drug Directorate, National Health and Welfare Department 2004-16, 2057, 2078, 2241-48
- McClenahan, R.G., Solicitor, Hoffman-LaRoche Limited 740-746
- MacEachen, Hon. A.J., Minister of National Health and Welfare 10-21
- MacIver, Callum, First Vice-President, Canadian Cystic Fibrosis Foundation 1661-75
- MacLeod, F.N., Senior Combines Officer, Combines Branch, Registrar General Department 2191, 2203
- Martin, J.C., Director, Administration, Finance, Smith, Kline & French 905-937

WITNESSES (Cont'd)

- Moriarity, Dr. A.J., Director of Research and Development, Smith, Kline & French	895-933
- Nowotny, C.A., Assistant Secretary, Hoffman-LaRoche Limited	714-756
- Pape, F.W., Executive Vice-President, Cyanamid of Canada Limited	662-665, 683-689
- Park, Dr. J.M., Member, Medical Advisory Board, Canadian Cystic Fibrosis Foundation	1664-74
- Pearce, Miss G., National President, Consumers Association of Canada	1133, 1155, 1169
- Peart, Arthur, M.S., General Secretary, Canadian Medical Association	380-405
- Peel, C.M., President, Canadian Drug Association	1568-1600
- Pernarowski, Dr. M., Vice-President, Consumers Association of Canada	1133-1169
- Pitcher, G.C., Vice-President, Canadian Wholesale Drug Association	1572-1601
- Plumptre, Mrs. A.F.W., Past President, Consumers Association of Canada	1143-53
- Poyntz, H.H., Director, General Require- ments, National Defence Department	1509-36
- Ritchie, Dr. K.S., Assistant Deputy Minister, Veterans Affairs Department	1506-48
- Robb, James, Legal Adviser, Ayerst, McKenna & Harrison, Limited	862, 866
- Robertson, R.W., Publisher, Medical Post	1234-49
- Rogers, C.A., Vice President, Managing Director, Parke, Davis & Company Ltd.	1027-56
- Ross, Hon. J.D., M.D., Minister of Public Health, Province of Alberta	2295-2302
- Sheldon, Michael, Assistant to General Manager, Smith, Kline & French	2192

WITNESSES (Cont'd)

	Page
- Showalter, Dr. H.A., Chief, Consumer Chemicals Division, Industry Department	1498-1545
- Smart, Russel, Member, Patent and Trademark Institute of Canada	1334-57
- Smith, Dr. H.L., Vice-President, Ayerst, McKenna & Harrison, Limited	833-866
- Steele, H.B., Ph.D., Associate Professor Economics, University of Houston, Texas; representing Alberta Government	2302-2400
- Stewart, Dr. Brian, Director, Pharmaceutical Research Canada Limited; Pharmaceutical Manufacturers Association of Canada	198-212, 1394-1438
- Stewart, D.J., Past President, Canadian Society of Hospital Pharmacists	1457-88
- Stovel, S.R., President, Cyanamid of Canada Limited	589-590, 637-693
- Thorson, J.T., Legal Adviser, Micro Chemicals Limited	1764-1803
- Turnbull, J.C., Executive Director, Canadian Pharmaceutical Association, Inc.	50, 69-89, 427-448, 1888-1929
- Walker, J.A., Executive Vice-President, Ayerst, McKenna & Harrison Limited	836-868
- Walker, R.R., Legal Counsel, Prescription Services Inc.	1850-72
- Weston, D.R., Secretary-Manager, Canadian Wholesale Drug Association	1567-1602
- Wigle, W.W., M.D., President, Pharmaceutical Manufacturers Association of Canada	93-143, 170-278, 1377-1438
- Wilkinson, W.A., President, Prescription Services Inc.	1847-71
- Wilson, C.E., Manager, Medical Post	1233-47

WITNESSES (Cont'd)

- Wilson, Laurence, Member firm Consulting Biologists	547-573
- Wilton, R.E., Canadian Pharmaceutical Association, Inc.	1917,1926
- Wright, Dr. G.F., President, Empire Laboratories Ltd.	1072-1112
- Wright, Dr. G.F., Prof. Chemistry, Uni- versity of Toronto; Research Consul- tant, Counsel, Canadian Drug Manu- facturers	496-505,1396-1438
Lists	2654-57,2709-11

